Author index

S = Supplement 2

A

Aagenæs, Ø 579
Aanstoot, H.-J. 917
Abe, K. 818
Acton, R.T. 104, 420
Adamson, U. 247
Ahrén, B. 871
Akai, H. 818
Åkerblom, H.K. 381, 388
Alcántara, A.I. 1163
Alcolado, J.C. 372, 640
Alford, F. 217
Allannic, H. 491
Altan, V.M. 572
Amemiya, S. 1159
Ampudia-Blasco, F.J. 703
Amthor, K.-F. 579
Anai, M. 504
Andersen, H.U. S82
Andersen, P.H. 82
Anderson, P. 36
Annibale, B. 797, 1265
Antsiferov, M. 170
Aoki, M. 104
Archer, D.B. 36
Archibald, V. 449
Arendarczyk, W. 731
Ari, N. 572
Arkhammar, P. 1121
Arnal, J.F. 879
Arner, P. 428
Aro, A. 381
Artlett, C.M. 500
Arundel, T. 1113
Asahina, T. 264
Asano, T. 504
Ashcroft, S.J.H. S21
Assmann, K.J.M. 313
Astrup, A.-S. 708
Atef, N. 677
Athens, M.A. 624
Awata, T. 210, 1159

B

Bach, J.-F. 337
Bach, J.F. S90
Baekkeskov, S. 917
Balsano, F. 308
Bangstad, H.-J. 483, 1172
Bar-On, H. 119
Barker, D.J.P. 150
Barnett, A.H. 372
Barnett, M. 671
Beacham, J. 166
Beck-Nielsen, H. 217
Becker, F. 365
Behmand, R.A. 730
Beis, C.S. 436
Bell, D.S.H. 104, 420
Bellini, C. 308
Bemelmans, M.H.A. 10
Ben-Sasson, R. 119
Benbow, S. 1056
Bendayan, M. 119
Bender, R. 703
Bennet, W.M. 166, 436
Bennett, P.H. 617
Berden, J.H.M. 313, 604
Berg, K.J. 483
Berg, T.J. 579
Bergamo, F. 1051
Berger, M. 170, 332, 377, 703
Berggren, P.-O. 1121
Bergsten, P. S11
Bergstrom, R.W. 524
Bertoli, G. 597
Bertrams, J. 471
Berts, A. S11
Betterle, C. 95
Bex, M. 808
Bhargava, R. 843
Biesenbach, G. 905
Biessels, G.J. 643
Bingley, P.J. 70, 365
Biro, P.A. 937
Bischof, F. 540
Bjerre, U. S82
Black, A.E. 222
Blanché, H. 842
Bleackley, R.C. 733, 833
Bloom, S.R. 166, 436
Bodkin, N.L. 127
Bodmer, C.W. 1056
Boel, E. 344
Boer, S.Y. de 75
Boitard, C. 337
Boitard, C. S90
Bolli, G.B. 713, 797, 1265
Bone, A.J. 466
Bonifacio, E. 365
Bonner-Weir, S. 22, 994
Born, J. van den 313
Bosi, E. 365
Bosse, G. 1154
Bott, U. 170
Bottazzo, G.F. 365, 846
Bouchard, C. 757
Boucher, B.J. 49, 1063
Bouillon, R. 552, 808
Boulanger, M. 969
Bourey, R. 401
Bouwens, L. 1088
Bradshaw, B.S. 624
Brand, C.L. 985
Brand Miller, J.C. 1280
Bravenboer, B. 408, 643
Brennan, G. 115
Brichard, S.M. 1065
Brinchmann-Hansen, O. 1172
Brockington, M. 372
Brodsky, I. 358
Brown, D.C. 889
Brownlee, M. 32, 145
Bruijn, J.A. 111, 313
Bruining, G.J. 917
Brunetti, P. 713, 797, 1265
Bucchini, D. 1178
Bürki, K. 1097
Burg, M.P.M. van der 111
Buschard, K. 1000
Buyse, I. 808
Buzzetti, R. 846
Byfield, P.G.H. 436
Byrne, C.D. 889

C

Cameron, N.E. 449, 651, 1209
Caputo, S. 911
Caretto, A. 95
Carey, F. 651
Carlberg, C. 441
Carlström, K. 428
Carpentier, J.-L. S117
Carrington, A.L. 43
Cassiman, J.-J. 808
Cerasi, E. S3
Ceriello, A. 440
Cetkovic-Cvrlje, M. 351
Chaillous, L. 491
Chakravarthy, U. 36
Chantelau, E. 223, 377
Chapman, J. 585
Charbonnel, B. 491
Chaturvedi, N. 765
Chen, Y.-D.I. 781, 843
Chiu, K. 182
Chiu, K.C. 104, 420
Christensen, C.K. 788
Christensen, P.D. 788
Christgau, S. 917
Christie, M.R. 365, 471
Chu, D.T. 1097
Chusney, G.D. 639
Ciofetta, M. 713, 797, 1265
Clark, P.M.S. 592, 889
Clemente, F. 1163
Clodi, M. 188
Cohen, D.K. 1097
Cohen, N. 842
Colagiuri, S. 1280
Cole, D.R. 466
Collier, F.McL. 671
Collier, G.R. 671
Collins, P. 1259
Conget, I. 177
Cook, J.T.E. 721, 1231
Cotter, M.A. 449, 651, 1209
Couper, J.J. 533
Couper, R.T.L. 533
Cox, A. 500
Cox, L.J. 889
Crepaldi, G. 1015
Crijns, F.R.L. 10
Crook, M.A. 639
Cuartero, B.G. S82
Curtin, A. 1259
Cusin, I. 1202
Cybal, M. 731

D

D'Alessio, D.A. 725
Dahl-Jørgensen, K. 483, 579, 1172
Daniels, T. 344
Dausset, J. 842
Davies, A.J. 466
Day, N.E. 889
De Feo, P. 1265
De Fronzo, R.A. 1025
De Hertogh, R. 855
De Mattia, G. 308
De Meyts, P. S135
Deacon, R.W. 1097
Deary, I.J. 257
Dedov, I.I. 170
Deegan, P. 1259
Deems, R.O. 1097
Deferrari, G. 1015
Del Prato, S. 1025
Del Sindaco, P. 797
Delamaire, M. 491
Delgado, E. 1163
Della-Zuana, O. 969
Desideri, G. 308
Després, J.P. 757
Devlin, J.T. 358
Di Francesco, L. 308
Di Leo, M.A.S. 911
Di Mario, U. 1015
Di Vetta, V. 517
Di Vincenzo, A. 713, 797, 1265
Dick, J.B.C. 439
Dines, K.C. 449, 651, 1209
Does, F.E.E. van der 1169
Donadon, V. 597
Donaldson, P.T. 155
Dooms, L. 808
Dougall, N. 257
Dowd, A. 394
Dowse, G.K. 1062
Drużyńska, J. 731
Dührkop, M. 1178
Duff, G.W. 500
Duhamel, M. 808
Duhault, J. 969
Dunbar, P.R. 1142
Dunger, D.B. 70
Durola, L. 1051

E

Ebeling, P. 202
Ebmeier, K.P. 257
Edelstein, D. 32
Efendic, S. 1121
Egan, M. 1113
Eizirik, D.L. 351
Elbein, S.C. 182
Elliott, R.B. 729
Elliott, T.G. 681
Elmansour, A. 491
Elving, L.D. 604

Emonds, M.-P. 808
Engerman, R.L. 141
England, J.D. 252
Epifano, L. 713, 797, 1265
Erkelens, D.W. 408, 643
Erlich, D. 585
Espinal, J. 969
EURODIAB IDDM Complications Study Group 278
Evans, J.L. 1097
Ewen, S.W.B. 49, 1063

F

Falsini, B. 911
Fanelli, C. 713, 797, 1265
Farese, R.V. 885
Faust, A. 1154
Federlin, K. 32
Fennessy, M. 937
Fernandez-Alvarez, J. 177
Ferrannini, E. 1, 1171
Ferrante, A. 533
Ferri, C. 308
Feskens, E.J.M. 1169
Fillers, W.S. 1097
Firth, R. 721
Flandre, P. 585
Fogh, J.M. 1178
Fontbonne, A. 953
Fossati, L. 1277
Franklin, W.A. 145
Franssila-Kallunki, A. 401
Fraser, R. 543
Fredman, P. 1000
Frenck, W. 377
Freychet, P.F. S186
Fridolf, T. 871
Frier, B.M. 257
Fröhlich, M. 75
Frölich, M. 111
Froesch, E.R. S179
Froguel, P. 585, 959
Froguel, Ph. 842
Fujimoto, W.Y. 524
Fujishima, M. 897
Fujita, M. 739
Fukuda, M. 22
Fuller, S. 358
Furuta, H. 536
Furuta, M. 536

G

Galante, P. 3
Gale, E.A.M. 70, 365
Gall, M.-A. 195
Galstyan, G.R. 170
Galuska, D. 270, 826
Gangnerau, M.N. 610
Gay, L.J. 517
Gembal, M. 731
Genovese, S. 365
Gerich, J. 697
Ghatei, M.A. 166, 436
Ghirlanda, G. 911
Giampietro, O. 1015
Gilbey, S.G. 166
Gilon, P. 1007
Gingras, D. 119
Girard, J. 1065
Gispen, W.H. 408, 643
Go, R.C.P. 104, 420
Goldenberg, R.L. 104
Goldstein, D.E. 252
Gomis, R. 177
Gonzalez, A.M. 500
Gonzalez, W. 879
Goodwin, G.M. 257
Gooszen, H.G. 111
Gordon, D. 439
Goto, Y. 863
Grabert, M. 925
Grafinger, P. 905
Grapengiesser, E. S11
Greco, A.V. 911
Greene, D.A. 1147
Grill, V. 351
Grobbee, D. 917
Grobbee, D.E. 1169
Groenhout, C. 408
Groop, L.C. 401
Groop, P.-H. 681
Gross, D.J. 1195
Grubin, C.E. 344
Gu, X.-X. 808
Guberski, D.L. 1186
Guertin, D.M. 1073
Guicherit, O.R. 111
Gustafsson, J. 61
Gylfe, E. S11
Gylling, H. 773

H

Haan, C.H.A. de 750
Häring, H.U. 3, S149
Hagopian, W.A. 344
Hagura, R. 1159
Halban, P.A. S65
Hales, C.N. 150, S162, 592, 889
Halsall, A. S155
Hamaguchi, K. 745
Hammersley, M.S. 214
Hammes, H.-P. 32
Handberg, A. 443
Haneda, M. 838
Hannaert, J.C. 15
Hansen, B.C. 127
Hansen, S.V. 1000
Hanson, R.L. 617
Hanssen, K.F. 483, 579, 1172
Harding, A.E. 372
Harik, S.I. 730
Harlan, D.M. 1277
Harrison, A.A. 1142
Hart, L.M.'t 1169
Hartmann, A. 483
Hasuo, Y. 897
Hattersley, A.T. 721, 1231
Hattori, M. 22
Hauguel-De Mouzon, S. 56
Havelund, S. 1178
Hawkins, M.M. 1287
Hayes, R. 115
Heickendorff, L. 286
Heidland, A. 567
Heine, R.J. 1169
Heinemann, L. 377, 703
Heinze, E. 925
Heise, J.W. 471
Heise, T. 703
Hellman, B. S11
Helqvist, S. S82
Hendrikse, P.H. 408
Henquin, J.-C. 1065, 1007
Hepburn, D.A. 257
Hepp, K.D. S108
Herberg, L. 3
Hermans, J. 313
Hermansen, K. 788
Herrera, P.L. 1277
Hibino, T. 1154
Hinokio, Y. 818
Hirai, S. 818
Hirst, S. 150, 592
Hitman, G.A. 937, 959, 1221
Hoffman, M. 182
Hofman, A. 917
Holl, R.W. 925
Holmberg, E. 1105
Holst, J.J. 985
Hommel, E. 511
Honer, C.M. 1097
Horie, M. 1082
Horio, F. 22
Horn, T. 1000
Horowitz, M. 543
Hother-Nielsen, O. 217
Houben, A.J.H.M. 750
Hougaard, P. 321
Howard, N.J. 1113
Howell, S.L. S30
Høyer, P.E. 443
Hu, Y. 610
Huarte, J. 1277
Hubmann, R. 905
Huby, T. 585
Huffelen, A.C. van 408
Hughes, S.J. 134, 863
Huijberts, M.S.P. 10
Hulinska, H. 1113
Hulinsky, I. 1113
Hussain, M. S179
Hutton, J.C. S48
Huvers, F.C. 750

I

Ikebuchi, M. 264
Ikeda, H. 1082
Inchiostro, S. 597
Inoue, K. 351
Inouye, H. 632
Inukai, K. 504
Ionescu-Tirgoviste, C. 331
Isami, S. 300
Ishida, H. 1082
Ishihara, H. 504
Ishii, D.N. 1073
Ishizuka, T. 632
Ito, T. 328
Ivarsson, S.A. 293
Iwamoto, H. 897
Iwamoto, Y. 210
Izui, S. 1277

J

Jaap, A.J. 214
Jacobsson, L.T.H. 617
Jaffe, M. 917
James, R.W. 585
Jami, J. 1178
Janko, O. 905
Jansen, J.B.M.J. 75
Jansen, J.J. 1169
Janssen, R.C. 420
Jansson, P.-A. 697
Jarrett, R.J. 945
Jéquier, E. 517
Jeanrenaud, B. S169, 1202
Jensen, A.G. 729
Jeppesen, J. 781
Jeremy, J.Y. 336
Jeron, A. 414
Jörgens, V. 170, 332
Johansson, B.-L. S99
Johansson, C. 91
Johnson, A. 1259
Johnston, D. 115
Jonas, J.C. 1007
Jones, C.N.O. 843
Jones, P.M. S30
Jørgensen, P.N. 985
Josefsen, K. 1000
Joseph, M.G. 491
Jun, H.S. 460
Jungmann, E. 441

K

Kämpe, O. 61, 293
Kahn, S.E. 725
Kaiser, W. 905
Kajita, K. 632
Kalland, T. 1195
Kamath, S. 1113
Kanazawa, Y. 210, 1159
Kappelle, A.C. 643
Karjalainen, J. 388
Karlsen, A.E. S82, 344
Karlsson, F.A. 61, 293
Karlsson, S. 871
Kashiwagi, A. 264
Kassi, G. 713
Katagiri, H. 504
Kato, I. 897
Kato, S. 1082
Katoh, H. 22
Kautzky-Willer, A. 188
Kawasaki, E. 818
Kawasaki, H. 818
Kayser, L. 443
Kellerer, M. S149
Kempler, P. 1168
Kerényi, Zs 1168
Kern, T.S. 141
Khandan-Nia, N. 166
Kidron, M. 119
Kiekens, R. S57
Kikkawa, R. 264, 838
Kikuchi, M. 504
Kim, G.S. 460
Kimura, A. 745
Kindmark, H. 1121
Kisanuki, K. 300

Kishikawa, H. 300
Kitaoka, H. 504
Kiyohara, Y. 897
Kleemann, R. 1154
Klein, J. C. 610
Klöppel, G. 1088
Knip, M. 381, 388
Knowler, W. C. 252, 617
Ko, I. Y. 460
Kockum, I. 1105
Kodama, H. 739
Köhler, M. 1121
Kofoed-Enevoldsen, A. 195
Koivisto, V. A. 202
Kolb, H. 471, 729, 1154
Kolb-Bachofen, V. 471
Kollind, M. 247
Koranyi, L. 401
Korytkowski, M. 697
Kowalczyk, M. 731
Koya, D. 838
Kristensen, J. S. 985
Kromhout, D. 1169
Kurashige, T. 476
Kuroyama, H. 536
Kuusi, T. 681
Kuzuya, T. 210
Kvetny, J. 729

L

Lacour, F. 969
Lahdenperä, S. 681
Lalli, C. 797
Lam, W. F. 75
Lamers, C. B. H. W. 75
Lampeter, E. F. 471
Landgraf, R. S1
Landin-Olsson, M. 344
Larger, E. S90
Larson, M. E. 141
Larsson, O. 1121
Lattimer, S. A. 1147
Laufgraben, M. J. 994
Laureys, J. 552
Laws, A. 948
Le Marchand-Brustel, Y. 56
Leahy, J. L. 994
Lecomte, P. 491
Ledet, T. 286
Leeuw, P. W. de 750
Lemieux, S. 757
Lemkes, H. H. P. J. 75, 313, 1169
Lemonnier, F. 610
Leonetti, D. L. 524
Leonetti, F. 1025
Lepore, M. 797, 1265
Lernmark, Å. S73, 344, 1105
Levy, J. C. 1231
Li, L. 344
Lier, H. J. J. van 604
Like, A. A. 1186
Lilja, B. 293
Limal, J. M. 491
Linder, S. 1121
Lindström, J. 401
Ling, H. 567
Ling, Z. 15, S11, S57
Lins, P.-E. 247
Lithell, H. 1044
Little, R. R. 252
Littleford, K. D. 533
Löhr, J.-M. 222
Lohmann, D. 471
Lorenzen, T. S82, 321
Lounamaa, R. 388
Ludvigsson, J. 91
Ludvik, B. 188
Lund, P. E. S11
Lund, S. 82
Lupien, P. J. 757

M

Maassen, J. A. 1169
MacCuish, A. C. 439
Macdonald, I. A. 689, 1241
Mackay, I. R. 1113
MacLeod, K. M. 257
Madsen, R. W. 252
Maerker, E. 3
Maggs, D. G. 689
Magrin, L. 95
Majid, A. 372
Malaisse, W. J. S36, 177, 442
Malik, R. 847
Mamo, J. C. L. 238
Mandeli, J. 336
Mandrup-Poulsen, T. S82
Mangili, R. 1015
Mann, J. I. 1287
Månsson, J. E. 1000
Margetts, B. M. 222
Marmot, M. G. 765
Marshall, M. O. 1000
Martin, S. 32, 1154
Martins, I. J. 238
Marynen, P. 808
Masclee, A. A. M. 75
Masson, E. A. 1056
Mathieu, C. 552
Matsuda, M. 1025
Matsumoto, C. 210, 1159
Matsumoto, M. 818
Maugendre, D. 491
Maxfield, E. K. 449, 651
Mayer, H. 540
McCance, D. R. 617
McCarthy, M. I. 959, 1221
McGinty, A. 36
McKeigue, P. M. 765
McKillop, J. 36
McLarty, D. G. 745
McNab, G. L. 155
McVeigh, G. 115
Melloul, D. S3
Mengel, A. 1216
Mennel, F. J. 540
Mennuni, G. 1051
Menzinger, G. 1051
Metcalfe, K. 937
Meyerhoff, C. 540
Micheelsen, J. 443
Michelsen, B. 344, 1105
Miell, J. P. 439
Miettinen, T. A. 773
Miles, K. A. 365
Miller, M. A. W. 336
Mirrlees, D. J. 651
Mistry, S. S155
Miura, K. 632
Miyabayashi, S. 818
Miyamura, N. 300
Miyata, T. 300
Moatti-Sirat, D. 610
Moberg, E. 247
Modarelli, F. 713, 797, 1265
Mogensen, C. E. 788, 1251
Mohan, V. 1221
Molenaar, J. L. 917
Mølgaard, H. 788
Møller Jensen, D. 729
Monticone, G. 1051
Moorjani, S. 757
Moran, A. 1036
Morgan, A. R. 733
Morgan, R. 372
Mormile, F. 1051
Moro, L. 95
Morton, N. E. 1221
Mosthaf, L. 3, S149
Mühlhauser, I. 170, 332
Mullokandov, E. A. 145
Murphy, J. R. 730
Murray, P. 664

N

Nadeau, A. 757
Nagashima, T. 632
Nagataki, S. 818
Nakamura, J. 1147
Nakamura, T. 533
Nakayama, K. 897
Nanjo, K. 536
Navalesi, R. 1015
Neale, T. J. 1142
Neil, H. A. W. 1231, 1287
Nelson, M. 222
Nerup, J. S82, 321
Newell-Morris, L. L. 524
Nielsen, F. S. 195
Nieuwenhuijzen Kruseman, A. C. 10, 750
Nieuwenhuizen, A. G. 871
Nikula-Ijäs, P. 401
Nilsson, P. 1178
Nilsson, T. 1121
Nishimura, C. 328
Nishio, Y. 264
Niven, M. 937
Nobel, E. de 604
Nolan, C. J. 976
Nolte, L. A. 270, 826
Nomiyama, K. 897
Nosadini, R. 1015
Nurjhan, N. 697

O

O'Dea, K. 671
Oey, P. L. 408
Özçelikay, A. T. 572
Öztürk, Y. 572
Özüari, A. 572
Ogawa, Y. 994
Ogino, Y. 225
Ohagi, S. 536
Ohkubo, Y. 300
Ohmori, S. 897
Ohmura, T. 897
Ohsawa, N. 504
Ohtomo, M. 818
Oka, Y. 504
Okada, S. 225
Okamoto, Y. 1082
Olichon-Berthe, C. 56
Omori, Y. 328
Ongemba, L. N. 1065
Onoda, M. 818
Orci, L. 1277
Ørskov, L. 1216
Ortmeyer, H. K. 127
Osmond, C. 150, 592
Østerby, R. 483
Ota, Z. 225
Ottesen, J. L. 1178
Ouweland, J. M. W. van den 1169
Owens, D. 1259
Owens, D. R. 640

P

Pacini, G. 188
Page, R. C. L. 1231
Palitzsch, K.-D. 414
Palmer, C. R. 889
Palmiter, R. D. 725
Pampanelli, S. 713, 797, 1265
Pampfer, S. 855
Parkin, H. M. 1241
Parving, H.-H. 195, 511, 708
Passa, Ph 585
Patiño, F. 334
Patrick, A. W. 1056
Peakman, M. 155
Pedersen, O. 82
Pedini, B. 95
Pei, D. 843
Pekiner, C. 572
Pénicaud, L. 677
Péraldi, P. 56
Permutt, M. A. 104, 182, 420
Perriello, G. 1265
Persaud, S. J. S30
Persson, H. 1000
Petersen, B. 559
Petruzzelli, M. 22
Pettitt, D. J. 252, 617
Pfeiffer, E. F. 540
Phillips, D. I. W. 150, 592
Pickup, J. C. 639
Pimenta, W. 697
Pinkney, J. H. 70
Pipeleers, D. 15, S57
Pipeleers, D. G. S11
Pitt, B. 664
Pociot, F. S82, 321
Poitout, V. 541, 610
Porciatti, V. 911
Portha, B. 677
Potock, M. H. N. 1287
Power, R. F. 833
Pozzilli, P. 640, 846
Prager, R. 188
Presotto, F. 95
Priestman, D. A. S155

Proietto, J. 976
Prud'homme, D. 757
Przepiera, E. 731
Pueyo, M. E. 879
Pussard, E. 879
Pyzdrowski, K. 1036

Q

Qin, H. 182
Quin, J. D. 439

R

Rabinovitch, A. 733, 833
Rabinowe, S. L. 293
Räsänen, L. 381
Rajotte, R. V. 833
Ramachandran, A. 1221
Rambotti, A. M. 713, 797, 1265
Randle, P. J. S155
Rasmussen, L. M. 286
Rasschaert, J. 177
Ravel, D. 969
Rayfield, E. J. 336
Reach, G. 541, 610
Reaven, G. M. 781, 843, 948
Redgrave, T. G. 238
Rees, A. 372
Rees, J. A. E. 640
Reid, J. J. 232
Reimers, J. I. S82
Rett, K. 3
Reynisdottir, S. 428
Richard, M.-F. 337
Rigamonti, G. 1015
Riggs, A. C. 104, 420
Rittershaus, C. 22
Robertson, R. P. 559, 1036
Robinson, A. M. 1241
Rössner, S. 428
Rohmer, V. 491
Rohner-Jeanrenaud, F. 1202
Rokos, H. 466
Rolin, B. 985
Roll, U. 1132
Rønningen, K. S. 745
Rooth, P. S112
Roseman, J. M. 104, 420
Rosen, K. M. 994
Rosenmann, E. 1195
Rossing, P. 195, 511, 708
Rothe, H. 1154
Rowley, M. J. 1113
Ruiz, J. 585
Russo, F. 1051
Rutgeerts, O. 552

S

Sai, P. 491
Sainsbury, A. J. 238
Saito, T. 210, 328
Saker, P. J. 721
Saleck, M. 32
Samuelsson, U. 91
Sandkuyl, L. A. 808
Sandvik, L. 579
Sanke, T. 536
Santeusanio, F. 1265
Santucci, A. 308
Satoh, Y. 818
Saukkonen, T. 381
Savage, M. W. 1056
Savilahti, E. 381
Sawtell, P. A. 70
Schade, U. 1154
Schaefer, L. 567
Schaefer, R. M. 567
Schalin-Jäntti, C. 401
Schaper, N. C. 750
Scheeser, J. 1132
Scherft, J. P. 111
Schiavi, R. C. 336
Schipper, J. 75
Schmidt, A. 703
Schmitz, A. 1251
Schmitz, O. 1216
Schneiter, Ph 517
Schölmerich, J. 414
Scholz, R. 3
Schrama, E. 313
Schuit, F. S57
Schumm-Draeger, P.-M. 441
Schutz, Y. 517
Scrimgeour, A. 358
Seaquist, E. R. 1036
Seifert, I. 471
Seifert, M. 925
Seino, Y. 1082
Sempé, P. 337
Sempe, P. S90
Sener, A. 177
Sensi, M. 440
Sharp, A. 1113
Shaw, J. A. G. 1231
Sheehan, P. 1025
Shi, C. L. S112
Shi, Y. 733, 917
Shichiri, M. 300
Shields, D. C. 1221, 1231
Shigeta, Y. 264, 838
Shinkawa, A. 897
Shore, A. C. 214
Shuman, W. P. 524
Sidenius, P. 1216
Sidi, H. 1195
Sigurdsson, E. 917
Silink, M. 1113
Silvestrini, R. A. 1113
Simmons, D. 930
Simonson, D. C. 1025
Simpson, L. O. 331
Sindelka, G. 377
Skard Heier, M. 579
Slaaf, D. W. 750
Slavin, S. 1195
Smedegaard Kristensen, J. 270
Smidt, U. M. 511, 708
Smith, F. E. 994
Smith, K. 439
Smith Pedersen, R. 729
Snehalatha, C. 1221
Sørensen, K. E. 788
Sorensen, O. 833
Spezia, R. 1015
Staines, A.- 845
Standl, E. 1132
Starke, A. A. R. 703
Starostina, E. G. 170
Stehouwer, C. D. A. 334
Stern, M. P. 624, 956
Sternberg, F. 540
Stevens, E. J. 43
Stimmel, B. 336
Stöger, H. 905
Stoffel, M. 721
Stolk, R. P. 1169
Stowers, J. M. 49, 1063
Strachan, J. 439
Straub, R. H. 414
Streli, C. 188
Struijker Boudier, H. A. J. 10
Stubbs, M. 1186
Stuby, U. 905
Stumvoll, M. 697
Suarez-Pinzon, W. L. 733, 833
Sugimoto, T. 838
Sundkvist, G. 293
Suzuki, K. 863
Suzuki, S. 818
Svendsen, I. 985
Swai, A. B. M. 745
Sweeney, M. G. 372

T

Täljedal, I.-B. S112
Takagi, Y. 264
Takeda, N. 632
Tamás, Gy 1168
Tamsma, J. T. 313
Tanaka, Y. 264
Taniguchi, O. 632
Taniguchi, T. 476
Tanimoto, T. 328
Tanizawa, Y. 104, 182, 420
Tappy, L. 517
Taskinen, M.-R. 681
Tattersall, R. B. 689, 1241
Taylor, R. 394
Teller, W. M. 925
Tengblad, S. 1044
Tengholm, A. S11
Teschner, M. 567
Tesfaye, S. 847, 1168
Teuscher, A. U. 1036
Thériault, G. 757
The Bart's-Oxford Study Group 70
Thies, U. 414
Thillet, J. 585
Thörne, A. 270
Thomas, T. H. 394
Thomaseth, K. 188
Thomé, V. 610
Thompson, C. S. 336
Thompson, G. H. 624
Thorsby, E. 745
Tilly-Kiesi, M. 681
Timsit, J. S90
Toivola, B. 344
Tomkin, G. H. 1259
Tomlinson, D. R. 43
Tomoda, T. 476
Tooke, J. E. 214
Toplak, H. 1167
Torlone, E. 713, 1265
Tosi, G. F. 846
Toyota, T. 818
Trautner, Ch 170
Tremblay, A. 757
Trimble, E. R. 36
Tsukuda, K. 504
Tsuura, Y. 1082
Tuomilehto, J. 381, 745, 937
Tuomilehto-Wolf, E. 745, 937
Turner, R. C. 721, 1231

U

Uccioli, L. 1051
Ueda, K. 897
Uehara, M. 300
Underhill, J. 155
Undlien, D. E. 745
Urakami, T. 1159
Uzu, T. 838

V

Vaag, A. 217
Vähäsalo, P. 388
Valdez, R. 624
Valverde, I. 1163
Van Obberghen, E. 56, S125
Van Schaftingen, E. S43
Vanderheyden, I. 855
Vassalli, J. D. 1277
Vassalli, P. 1277
Vats, A. 155
Vedel, P. 82
Veerkamp, J. H. 313
Velloso, L. A. 61, 293
Verchere, C. B. 725
Vergani, D. 155
Verge, C. F. 1113
Vessby, B. 1044
Vestergaard, H. 82
Vettor, R. 1202
Viberti, G. C. 639, 681
Villa-Komaroff, L. 994
Villanueva-Peñacarrillo, M. L. 1163
Villar-Palasi, C. 885
Vinten, J. 443
Virtanen, S. M. 381
Viswanathan, M. 1221
Væth, M. 1251

W

Waer, M. 552
Wagner, R. 365
Wahl, P. W. 524
Wahren, J. S99
Wahrenberg, H. 428
Wainscoat, J. S. 1231
Waldhäusl, W. 188
Wallberg-Henriksson, H. S99, 270, 826
Wang, R. N. 1088
Wang, T. W. M. 889
Ward, J. D. 500, 847, 1168
Wareham, N. J. 889
Warnock, T. 155
Warren-Perry, M. 721

Wascher, T.C. 1167
Wassmuth, R. 1105
Way, K.J. 232
Webb, R.C. 664
Weening, J.J. 313
Weilguny, D. 1178
Weiss, L. 1195
Welsh, K. 500
Wetzels, J.F.M. 604
Whalen, L.R. 1073
Wiedmeyer, H.M. 252
Wierzbicki, M. 969
Wieslander, J. 313
Wilding, J.P.H. 166
Wilikens, A. S57
Wilkin, T.J. 466
Wilkinson, R. 394
Williams, D.R.R. 889
Williams, G. 1056
Wilson, A.G. 500
Wilson, G.S. 610
Wilson, R.M. 500
Winqvist, O. 61
Wójcikowski, Cz 731
Wolffenbuttel, B.H.R. 10
Worm, M. 1216
Woude, F.J. van der 313
Wuu, Y.D. 855

Y

Yamaguchi, I. 739
Yamamoto, M. 632
Yamanouchi, T. 504
Yano, N. 22
Yano, T. 300
Yasuda, K. 632
Yazaki, Y. 504
Yki-Järvinen, H. 401
Ylönen, K. 381
Yoon, J.W. 460
Yoshitake, T. 897
Young, D.A. 1097
Young, M. 223

Z

Zamani Ghabanbasani, M. 808
Zanchetta, R. 95
Zanette, G. 597
Zarjevski, N. 1202
Zazgornik, J. 905
Zhang, H.-J. 559
Zhang, Y. 610, 721
Zhou, M.-Y. 781
Ziegler, A.-G. 1132
Zierath, J.R. 270, 826
Zimmet, P. 671
Zimmet, P.Z. 1113
Ziv, E. 119

Subject Index

KEY: A = Abstract in Supplement 1; b = Book review; c = Correspondence; r = Review or Debate; S = Supplement 2 (Minkowski Prizewinner Symposium); w = Workshop report

A

ACE *[see* Angiotensin – converting enzyme*]*
Acetaminophen *[see* Paracetamol*]*
Acetyl-CoA – carboxylase – expression – vanadate, effect of 1065
Acetylator status – diabetic nephropathy A 191
Acromegaly – insulin resistance – bromocriptine, effect of A 212
$ACTH_{4-9}$ analogue ORG 2766 *[see also* Neuropathy – diabetic*]* 408
Adenosine – analogue – formycin A *[see* Formycin A*]*
Adhesion molecule – diabetes A 25
– intercellular – modified recombinant A 83
Adipose tissue *[see also* Fat*]* – catecholamine resistance in upper-body obesity 428
– glucose uptake and lactate production – human A 129
Adrenoceptor – α_2 – antagonist – hypoglycaemia, effect in A 166
– blocking agent – deriglidole – metabolic effect A 132
– SL 84.0418 – amylin levels, effect on A 211
Adrenoceptor – β – blocking agent – diabetic nephropathy 604
– β_3 – agonist – ZD2079 – glucose tolerance, effect on A 212
– expression – adipose tissue – upper-body obesity 428
Adrenocorticotrophic hormone *[see* ACTH*]*
AGE *[see* Glycation – advanced end-product*]*
Ageing A 182
Albert Renold Fellowship 1994 – Juntti-Berggren, Lisa *EASD News Section 10/94 45*
Albumin excretion rate A 192–A196
– diabetic nephropathy progression 511, 604
– pregnancy – Type 1 diabetes 905
Albuminuria – magnesium, serum 639c
– progression – blood pressure and A 23
– – glycaemic control, effect of 1251
– aminoguanidine, effect of – streptozotocin-diabetic rat 10
Alcohol – hypoglycaemia, effects in A 165
Aldose reductase *[see also* Glyceraldehyde*]* – erythrocyte – diabetic retinopathy and 328
– inhibitor – diabetic neuropathy – primary prevention A 177
– – dog neuropathy, effect on 141
– – insulin secretion, effect on A 12
– – nerve, effect on – mechanism 651
– – ZD5522 651
– overexpression – phosphatidylsorbitol, membrane 1147
Alpha-blocker *[see* Adrenoceptor – α*]*
Alpha-glucosidase inhibitor – miglitol A 211
Aminoguanidine *[see also* Glycation – advanced end-product*]*
– albumin excretion, effect on – streptozotocin-diabetic rat 10
– retinopathy, inhibition of – hypertensive rat 32
Amputation risk – diabetes A 205
Amylin A 51, A 115–A117
– analogue – tripro-amylin – therapeutic effects A 72
– assay – two-site immunoassay A 117
– diabetes, in *EASD News Section 2/94 11*
– expression – glycation, role of A 68
– insulin secretion, effect on – arginine-stimulated 436
– – transgenic mouse 725
– insulin sensitivity, no effect on in human 166
– overexpression – transgenic mouse 725
– renin, plasma, effect on A 46
– secretion – insulin resistance, in 188
Amyloid – fibril formation from amylin A 117
Angiotensin converting enzyme – gene – heart disease risk – diabetes A 34
– inhibitor – bradykinin, effect on 300
– – bradykinin/NO, effects on A 71
– – diabetic nephropathy 511, 604
– – – progression A 188
– – glomerular hyperfiltration A 187
– – insulin sensitivity and 300, A 124
– – ramipril 664
– – sulphydryl group 300
– – Type 2 diabetes, in A 140
– – vasomotor response, effect on 664
Anti-oxidant – probucol – diabetic neuropathy protection – rat 449
Antibody – adrenal – Type 1 diabetes A 91
– carboxymethyllysine – glucoxidation products, reaction with A 68
– cow's milk protein – risk of Type 1 diabetes 381
– GAD – 65kD in Type 1 diabetes A 95
– – – HLA A 85
– – assay – radioligand binding 344
– – autoimmune polyendocrine syndrome 1 61
– – autonomic function and – diabetes 293
– – chronic pancreatitis, not induced by 471
– – cross-reactivity A 63
– – isoform-specific – Type 1 diabetes 344
– – prediction of Type 1 diabetes 917, 491
– – Type 1 diabetes 1113, S 73
– – – marker of A 64
– – – seasonality & sex differences A 56
– gastric parietal-cell & intrinsic factor – Type 1 diabetes A 91
– glucagon – monoclonal 985
– insulin – assay – RIA A 90
– islet-cell – 51kDa – autoimmune polyendocrine syndrome 1 61
– – 64kDa – risk of Type 1 diabetes 491
– – 69kD antigen A 64
– – antigen – GM2–1 ganglioside A 56
– – chronic pancreatitis, not induced by 471
– – combined specificities – Type 1 diabetes A 56
– – diabetes – Type 1 1113, S 73
– – – Type 2 A 86
– – mouse cross-reactive – risk of Type 1 diabetes 491
– – pancreatectomy, following – rat A 77
– – prediabetes Type 1 388
– – prediction of Type 1 diabetes 917, A 55
– – selective *vs* whole pattern 95
– – species specificity – gestational diabetes A 58
– – staining pattern – progression to diabetes 365
– – sympathetic nerve antibody and 293
– sulphatide 1000
– sympathetic nerve – islet-cell antibodies and 293
– thyroid peroxidase – diabetes – Type 1 1113
– vagal nerve – GAD antibody and 293
Antidiabetic agent *[see* Hypoglycaemic agent*]*
Antigen, islet-cell – 38kDa – delayed expression in diabetic BB rat 460
– 69kD – distribution A 83
– GM2–1 ganglioside – distribution A 83
Antioxidant – α-lipoic acid – cataractogenesis, inhibition of A 211
– – glucose transport, effect on – *fa/fa* rat heart A 211
– – skeletal muscle, effect on – GLUT-4 A 60
– probucol A 210
Antioxidative capacity – serum A 65
Apolipoprotein – (a) – isoforms – coronary heart disease – diabetes – Type 2 585
– A-IV – macrovascular disease and – Type 2 diabetes A 145
– A1 – gene – promoter – coronary heart disease and A 145
– B-48 – diabetes – Type 2 1259
– B-100 – VLDL – hepatic secretion – hyperinsulinaemia, effect of A 147
– diabetes – Type 2 – cardiovascular risk factor? A 200
– E – amylin, association with – primate islet A 51
– isoforms A 87
Apoptosis – insulin-secreting cell A 91
– islet B-cell – BB rat A 96
Arachidonic acid – insulin secretion, role in S 30
– metabolism – diabetes A 103
Areca catechu – diabetogenic effect – human? 1062c
– diabetogenic effect – mice 49
Artery – aorta – diabetes – human 286

- contraction – streptozotocin-diabetic rat aorta – vanadyl sulphate 572
- media – diabetes 286
- stiffness – diabetes – women A 202

Ascorbic acid – glycation, inhibition of – streptozotocin-diabetic rat 731 c

Ashcroft, S J H – Minkowski Award 1979 S 21

Atherosclerosis – quantitation A 54

Atrial natriuretic peptide – insulin & glucose responses to 308
- diabetic autonomic neuropathy A 79

Audit – clinical *[see* Peer review*]*

Autoimmune, autoimmunity
- diabetes – Type 1 1113, S 73, S 90
- polyendocrine 365, A 90
  - islet-cell antibodies 95
  - syndrome 1 – islet-cell antibodies 61
  - Type 1 diabetes 95

B

B-cell, islet *[see also* Islet; Insulin – secreting cell*]* – Ca^{2+} A 69
- – amino-acid secretagogues, effect of A 70
- – desensitisation A 107
- – oscillation S 11
- – – Ba^{2+} proxies A 106
- – – culture duration and A 106
- – – impaired glucose tolerance 1121
- – – Sr^{2+} proxies, use of A 105
- culture – rat 15
- cytokine, effect of – DNA fragmentation 733
- cytoprotective enzymes A 82
- cytotoxicity A 82
  - interleukin-1 – strain, effect of A 93
  - metabolic activation, protection by A 97
- destruction S 82
- exocytosis A 76
  - Ba^{2+} and Sr^{2+} proxies for Ca^{2+} A 107
  - control A 69
  - hot spots A 106
- flow cytometry S 57
- function – diabetes – Type 1 – prediction at diagnosis A 156
- GLP receptor A 118
- glucocorticoid, effect of A 212
- glucoreceptor – glucokinase? 442 c
- glucose metabolism S 36
- glucose sensitivity – streptozotocin-diabetic rat – neonatal 351
- glucotoxicity – Type 2 diabetes, role in S 36
- GLUT-2 – virus-induced diabetes, unaffected in – BB rat 1186
- granule, insulin secretory – membrane proteins cloned A 76
- heterogeneity S 57
- ion channels – redox state and A 104
- isolation – autofluorescence-activated sorting A 38
  - calcium-indicator fluorochrome flow cytometry A 100
- K^+ channel – voltage-activated – nucleotides and A 60
- K^+_{ATP} channel – ATP/ADP ratio, effect of A 11
  - dihydroxyacetone, effect of – GK rat 1082
  - nucleotides, effect of A 61
- origin – ductal cell – cytokeratin marker A 99
- osmotic swelling, effect of A 104
- pH A 105
- phosphorylation S 21
- protein kinase S 21
- purinergic receptor agonist A 105
- regeneration – gene 994
  - streptozotocin, following – neonatal rat 1088, A 98
- streptozotocin, effect of *[see* Streptozotocin; Rat – streptozotocin*]*

Benzodiazepine receptor – islet A 111

Beta-blocking agent, adrenergic *[see* Adrenoceptor – β*]*

Beta-cell *[see* B-cell, islet*]*

Betel nut, diabetogenic effect of – human? 1062 c
- mouse 49

Biliopancreatic bypass surgery – morbid obesity – follow-up A 132

Bioartificial pancreas A 215–A 217

Biography – Macleod, JJR 641 b

Biopterin as a macrophage activity marker – BB rat insulitis 466

Birth – hyperinsulinaemia at – ethnic differences 930
- weight *[see also* Fetal – growth*]* – adult glucose tolerance, effects on A 70
  - insulin & C-peptide in cord blood and 930
  - perinatal morbidity and – maternal diabetes A 172
  - thinness – adult glucose tolerance following – rat A 171
  - – adult insulin resistance following 150, 624
  - – adult skeletal muscle metabolism following A 57
  - Type 2 diabetes and S 162

Blood – flow *[see also* Skin*]* – cerebral – diabetes 257, 643 r, A 26
  - – hypoglycaemia 257
  - endoneurial – endothelin 1, role of – streptozotocin-diab. rat 1209
  - – streptozotocin-diabetic rat 449
  - – – aldose reductase inhibitor effect 651
  - epineurial – diabetic neuropathy, role in 847 r
  - forearm – hyperglycaemia, effect of 750
  - fuel homeostasis and – human A 128
  - islet – diabetic rat 677
  - leg – hyperinsulinaemic clamp A 19
  - mesentery – diabetes A 199
  - muscle – hyperglycaemia, effect of 750
  - – insulin, effect of A 20
  - nerve – diabetic rat 43
  - nitrate, effect of – diabetes 115
  - skeletal muscle – Type 1 diabetes A 178
  - skin – diabetic neuropathy A 180
  - – foot A 24
  - – hyperglycaemia, effect of 750
  - – impaired glucose tolerance, in 214
- group – Lewis – insulin resistance syndrome A 88
- pressure – ambulatory – albumin excretion rate – Type 2 diabetes A 193
  - – insulin sensitivity and A 22
  - – microalbuminuria, in A 194
  - diabetic nephropathy progression, effect on 1251
  - insulin, role of A 142–A 144
  - nocturnal – albumin excretion rate and A 143
  - salt sensitivity – diabetes A 45

Body – composition – dual X-ray absorptiometry scanning A 127
- temperature *[see* Thermoregulation*]*

Boitard, C – Minkowski Award 1991 S 90

Bone – diabetes A 27
  - childhood A 18
- diffuse idiopathic skeletal hyperostosis – insulin resistance syndrome, in A 148
- mineral density – diabetes – Type 2 A 149, A 157

Bradykinin – angiotensin converting enzyme inhibitors, effect of 300

Brain – function – diabetes 643 r

Breast-feeding – diabetes incidence and 91, 381

BRLP-42 *[see* Hypoglycaemic agent – BRLP-42*]*

Bromocriptine – insulin resistance reduced by – acromegaly A 212

Brown adipose tissue – deficiency – transgenic mouse – obesity A 71

C

C-peptide – cord blood – New Zealand 930
- diabetes – Type 1 – duration of diabetes A 183
- function S 99
- renal effect A 187
- urinary – MELAS syndrome, reduced in 818
- vascular reactivity, effect on A 202

Calcitonin – gene – related peptide *[see* CGRP*]*
- salmon $_{8-32}$ – amylin antagonism – insulin secretion, effect on A 116

Calcitriol – NOD mouse, effect in 552

Calcium – channel – blocking agent – hereditary hypercholesterolaemic rat, in A 147

Camillo Golgi Lecturer 1994 – Tooke, John *EASD News Section 10/94 44*

Cyclic AMP – insulin secretion, role in S 30

Capillary – permeability – aminoguanidine, effect of 10
  - C-peptide and S 99
  - microalbuminuria and – diabetes – Type 1 A 196
- pressure – diabetes – Type 2 A 27
- steal A 203

Carbon monoxide – islet A 112

Carboxypeptidase – islet B-cell 61

Cardiovascular – mortality – ethnic differences – London 765
- risk factor *[see also* Apolipoprotein – A; Lipoprotein – (a)*]*
  - Afro-Caribbean *vs* European Londoners 765
  - apo(a) – diabetes – Type 2 585
  - diabetes A 200–A 203, A 138
  - hyperinsulinaemia 945 r, 953 r

– – impaired glucose tolerance, in 524
– – insulin resistance 597, 948r
– – microalbuminuria 1287c
– – – diabetes 788, A7
– – sex differences – fat distribution, role of 757
Carpentier, J-L – Minkowski Award 1987 S117
Catalase *[see* Oxygen – free radicals – scavengers*]* A190
Cataract – S-88–0773, delay by – diabetes A206
Catecholamine – glucose transport, effect on – cardiomyocyte – diabetes A60
– insulin secretion, effect on A109
– islet, effect on – transplanted S112
– noradrenaline – vascular response – hyperglycaemia effect 750
– postural response – hypoglycaemia, effect of 1241
Cathepsin – renal – streptozotocin-diabetic rat 567
Cell – B; Beta *[see* B-cell, islet*]*
Cell – insulin-secreting *[see* Insulin – secreting cell*]*
– membrane – composition – diabetes – phosphatidylsorbitol 1147
– – fluidity – insulin sensitivity and A137
– T *[see* Lymphocyte – T*]*
Central nervous system – streptozotocin-diabetic rat A73
Cerasi, E – Minkowski Award 1974 S3
Cerebral – glucose uptake – *fa/fa* rat S169
CGRP (Calcitonin-gene-related peptide) – receptor – amylin, effect of A116
Cheiroarthropathy – measurement – glycaemic control, effect of A149
Childhood – diabetes A18
Chinese hamster, diabetic – Chig/Han – GLUT-2 expression A113, A114
– islet B-cell function A43
Chlorogenic acid *[see also* Glucose – 6-phosphatase – inhibitor*]* A134
Cholesterol – absorption – inhibition 773
Cholesterol – lowering agent *[see* Hypolipidaemic agent*]*
Chylomicron – clearance – streptozotocin-diabetic rat 238
Cimetidine *[see* Histamine – H_2 receptor antagonist*]*
Clamp – euglycaemic – hyperinsulinaemic 797
– – – blood pressure & sympathetic activity A142
– – – hemipancreatectomy, following 1036
– – – human 1025
– – – mouse 1097
– – – pregnant rat 976
– – hypoglycaemic agent characterisation, in 703
– hyperglycaemic – human 1025
– – hyperinsulinaemic – hemipancreatectomy, following 1036
– – hypoinsulinaemic – nerve function – human 1216
– hypoglycaemic – hyperinsulinaemic 797
Claud Bernard Lecture – 1994 – Reaven, Gerald *EASD News Section 10/94 41*
Coagulation & anticoagulation – fibrinolysis – diabetes – Type 2 A197
– monocyte tissular factor – diabetes – pentoxifylline, effect of A13
– Protein C – resistance – Type 1 diabetes, decreased in A13
– thrombomodulin – microalbuminuria, in A194
Cockroft-Gault formula for creatinine clearance 708
Coeliac disease – diabetes – Type 1 1113
Cognitive function *[see also* Brain; Central N.S.; Hyperinsulin'a; Hypoglyc'a; Psychology*]*
– diabetes 643r
– cerebral blood flow A26
– hypoglycaemia, effect of – direct insulin effect? A47
Collagen – Type IV – synthesis – glycaemic control – Type 2 diabetes A189
Collagenase – renal – streptozotocin-diabetic rat 567
Complications of diabetes – glycaemic control and 1172r
– reversibility – islet transplantation, following A217
– risk factors – Ukraine A200
Congenital abnormality *[see* Fetus – malformation*]*
Contraception A174
Control subjects, selection of 845c
Costus speciosus – serum glucose, effect on – rat A213
Creatinine clearance – Cockroft-Gault formula 708
Cryopreservation – islet A217
Culture – islet B-cell – rat 15
Cyclosporin – glucose tolerance, effect on A212
Cytochrome P-450 – hepatic – diabetes A130
Cytokine – insulitis – NOD mouse 1154
– islet, effect on – DNA fragmentation 733
– – NO and CO mediation A112, A53
– islet, production by – human A96
– mRNA – islet – NOD mouse 833
– Type 1 diabetes S82

D

DCCT *[see* Diabetes – Control & Complications Trial *]*
De Meyts, P – Minkowski Award 1981 S135
Death – certification – diabetes A155
Diabetes – care – Eastern Europe 332c
– – – Moscow 170
– – evaluation *[see also* Education; Peer review; Psychology*]* A176–A177
– – glycaemic control, importance of 1172r
– childhood A18
– Control & Complications Trial (DCCT) – haemorheology A26
– – implications for diabetes care 1172r
– control *[see* Glycaemic control*]*
– gestational *[see also* Glucose – tolerance – gestational; Pregnancy*]*
– – diagnostic criteria A174
– – glucokinase gene 104
– – screening – France A58
– mitochondrial – Japan 504
– treatment – unproven efficacy, agents with – Germany A27
– Type 1 – animal model – TNFα-expressing transgenic mouse 1277
– – animal models S90
– – breast-feeding, protection by 91
– – childhood – hypoglycaemia 70
– – – presentation 70
– – disease-modifying therapy – insulin A92
– – – nicotinamide A64
– – – – desferioxamine with A209
– – – probucol? A210
– – environmental factors – cow's milk 381
– – incidence *[see* Epidemiology*]*
– – pathogenesis S82, S90, S73
– – preclinical phase *[see* Prediabetes – Type 1*]*
– – presentation 70
– – remission induction – insulin resistance following A135
– – T-cell subsets 155
– – viruses, role of – cytomegalovirus 222c
– Type 2 – animal model A112
– – – *db/db* mouse 739
– – – GK Wistar rat 863, 885
– – – *Psammomys obesus* (sand rat) 671
– – birth-weight preceding 592
– – pathogenesis S162
– – – debate 217r
– – – ethnic differences? 897
– – – insulin resistance 897
– – preclinical phase *[see* Prediabetes – Type 2*]*
– – secondary drug failure – insulin resistance & hypertension A141
Diagnostic accuracy – receiver-operating characteristic plot – GAD antibody 344
Diarrhoea – diabetic – breath hydrogen testing A184
Diet – alcohol – metabolic effects – diabetes A159
– carbohydrate – diabetes prevalence and 1278r
– diabetes – liberal 332c
– eating behaviour – diabetes A175
– fat – high – insulin resistance induction – rat A39
– – monounsaturated – diabetes – Type 2 A159
– – oleic acid – LDL, effect on A40
– – risk of Type 2 diabetes A39
– – short-chain fatty acid – metabolic effect A129
– fish oil – diabetes A67
– – glucose tolerance, effect on – hypertension A45
– – hypertriglyceridaemic rat, effect in A145
– – lipid peroxidation increased A137
– – metabolic effects – insulin resistance – rat A39
– – prostacyclin I_2-thromboxane A_2 system, effect on in NIDDM A158
– – skeletal muscle GLUT-4 expression, effect on A124
– infancy – cow's milk – risk of Type 1 diabetes 381
– insulin response, effect on A158
– measurement – editorial guidelines 222c
– prehistoric changes – diabetes and 1278r
– protein – animal *vs* vegetable A40

– – diabetes prevalence and 1278r
– survey – diabetic *vs* non-diabetic subjects A39
Dihydroxyacetone – islet B-cell, effect on – K^+_{ATP} channel – GK rat 1082
DNA *[see also* Gene; Polymerase chain reaction; Sequence-spec.oligonucleotide*]*
– damage – glycation products, by 145
– – islet – Tumour necrosis factor-α with interferon-γ A44
– fragmentation – islet B-cell – cytokine-induced 733
– sequence-specific oligonucleotide – HLA 808
Dog – diabetic – nerve conduction 141
– galactosaemic – nerve conduction 141
Dyslipidaemia *[see also* Lipoprotein; Cardiovascular – risk factor*]*
– lipid-lowering drugs, effect of – Type 2 diabetes A147

E

EASD – Abstracts of 30th Annual Meeting, Dusseldorf, 1994 (Suppl 1) A1-A218
– Minutes of 29th General Assembly, Istanbul, 1993 *(Suppl 1) I*
– Scientists Training Course *EASD News Section 10/94 47*
– Study Group *[see also* Study Group*]*
– – AIDSPIT (Artificial Insulin Delivery Systems, Pancreas & Islet Transplantation)
– – – *EASD News Section: 6/94 23w, 8/94 33w*
– – Diabetic Nephropathy (NEURODIAB) *EASD News Section: 11/94 53w, 2/94 12*
– – Metabolism and Insulin Action *EASD News Section 3/94 16*
– – Pancreatic Islet *EASD News Section 7/94 27w*
Eastern Europe – diabetes care 332c
– Russia 170
Echocardiogram – diabetes A187
Editorial 1, 1178
Education – diabetes – evaluation A27, A175, 170
– foot-care – evaluation A205
EGPD1 (European Group: Prediction & Prev'n Type 1 DM) *EASD News S'n 8/94 37w*
EIMA (enzymimmunometric assay) *[see also* Insulin – assay*]*
Elastin peptides – macroangioapthy marker – diabetes A202
Electrocardiogram – diabetes – QTc A186
– diabetic autonomic neuropathy – QT dispersion A8
– insulin resistance – QT prolongation A74
– signal-averaged – diabetes A200
Electroretinogram – focal – Type 1 diabetes 911
Eli Lilly/EASD Res. Fellowship 1994 – Sjoholm, Åke *EASD News Section 10/94 46*
Embryo – blastocyst – diabetes – carry-over effect – rat 855
– diabetes A80
– oxidative stress – maternal diabetes A171
Endocytosis – insulin receptor S117
Endothelial *[see also* Glycosaminoglycan*]*
– adhesion molecule – diabetic retinopý, in A36
– cell – glutathione redox cycle – high glucose, effect of 264
– – monocyte chemoattractant protein-1 expression A14
– – Na^+/H^+ counterport – glucose, effect of A192
– – regeneration – hyperglycaemia – aminoguanidine effect A54
– – umbilical vein – human 264
– function – diabetic nephropathy A13
– vascular reactivity, role in – streptozotocin-diabetic rat 664
Endothelin – 1 – antagonist – BQ-120 1209
– 1 – diabetic neuropathy, role in – streptozotocin-diabetic rat 1209
– – retinal pericyte, effect on 36
– 1–21 – diabetes A55
– plasma 333c
– – diabetic autonomic neuropathy A198
– urinary – BB rat A151
Energy – expenditure – IGF-I, effect of S179
– metabolism in obesity – follow-up after biliopancreatic bypass surgery A132
Environmental factor – diabetes – Type 1 – cow's milk 381
Epidemiology *[see also* Mortality; Risk*]*
– betel nut chewing 1062c
– birth weight & fetal hyperinsulinaemia – New Zealand 930
– cardiovascular risk factor – diabetes A201
– complications of diabetes A153
– – EURODIAB study 278
– diabetes – ethnic variation – prehistoric dietary changes in 1278r
– – internat. study group *EASD News Section 7/94 28w*
– – Type 1 – Bulgaria A155
– – – Lithuania
– – – Peru A154
– – – rising incidence – hygiene, role of? 729c
– – – Sardinia A154
– – – Slovakia A154
– glucose intolerance – Afro-Caribbean *vs* European Londoners 765
– hypertension – diabetes A153
– impaired glucose tolerance – Japanese-Americans 524
– insulin resistance – Japanese 897
– lipoproteins – Afro-Caribbean *vs* European Londoners 765
– maternally-inherited diabetes with deafness 1169c
– microalbuminuria – glucose tolerance and A16
– obesity – diabetes A153
Erythrocyte – ageing – ATP and ion flux – diabetes A182
– GLUT-1 – stability 730c
– lithium efflux – insulin & IGF-1, effects of A192
– membrane – fluidity – Na^+/Li^+ countertransport 394
EURODIAB – IDDM complications study 278
Evaluation – diabetes care *[see* Diabetes – care – evaluation; Education; Peer review; Psychology*]*
Evening primrose oil – nerve, effect on – streptozotocin-diabetic rat 331c
Evolution of diabetes susceptibility – prehistoric dietary changes 1278r
Exercise – fuel homeostasis and – forearm blood flow study A128
– metabolic effect A161
– protein catabolism following – Type 1 diabetes 358
– weight reduction, role in – diabetes A160
Extracellular matrix – diabetes 313
Eye *[see also* Cataract, Pupil, Retina, Retinopathy, Visual*]* – diabetes A206–A209
– sulphatide 1000

F

Factor analysis – pupillary light reflex 414
FAD-glycerophosphate dehydrogenase – islet – Type 2 diabetes 177
– purification – RINm5F cells A101
– Type 2 diabetes S36
Family study – diabetes – Type 1 – islet-cell antibodies 491
– – – lymphocyte subsets 1132
– – – progression to diabetes 388
– – – recurrence rate – geographical variation A6
– – – recurrence risk 321
– – – T-cell subsets 155
– – Type 2 959r, A85
– – – GLUT-4 expression 401
– – – insulin resistance A88
– – – lipoprotein (a) A145
– – – maternal inheritance – age at onset A89
– – – South India 1221
– microalbuminuria – cardiovascular disease A23
– obesity – hyperinsulinaemia in relatives A138
Fat *[see also* Adipose; Diet*]* – distribution – sex differences in man 757
– – visceral – diet, effect of – OLETF rat A160
Fatty acid – composition – islet – D-glucose, effect of A101
– composition – serum – insulin sensitivity and 1044
– – skeletal muscle phospholipid – insulin sensitivity 1044
– essential – nerve, effect on – streptozotocin-diabetic rat 331c
– glucose oxidation, role in S155
– insulin secretion, effect on A11
– non-esterified – fibrinolysis, role in – Type 2 diabetes A14
– – glucose production, effect on A134
– – metabolic regulation, role in 202
– – ω–3 – C-peptide and – Type 1 diabetes A128
– – pulsatile release A128
– – suppression – hypertriglyceridaemia, in 889
– synthase – expression – vanadate, effect of – streptozotocin-diabetic rat 1065
Fetus – insulin secretion – rat 134

– malformation – maternal diabetes A 172
Fibrinolysis *[see* Coagulation & anticoagulation*]*
Fibroblast – Ca^{2+} – glucose, effect of – hypertensive diabetics A 46
– premature ageing – diabetic nephropathy progression and A 34
Fibronectin – microangiopathy marker A 196
Ficus carica leaf – hypertriglyceridaemia, effect in – streptozotocin-diabetic rat A 213
Flow cytometry – islet B-cell S 57
Flutamide *[see* Hyperandrogenism*]*
Foot – diabetes A 24, A 203–A 205
– – amputation – Netherlands A 24
– – oximetry 1051
– – transplant recipients A 203
– – ulcer risk factors A 24
– postural instability – diabetic neuropathy A 205
– pressure distribution – diabetic neuropathy A 25, A 204
Formycin A – insulin secretion, stimulation of A 60
Froesch, E R – Minkowski Award 1967 S 179
Fructose – 6-phosphate – glucokinase regulation, role in S 43

G

Galanin – insulin secretion, effect on A 21
Gall-bladder – motility – glucose, effect of 75, A 185
Galvanic skin response – diabetic foot 1051
Gastric emptying in diabetes 543 r, A 183
– amylin, effect of – BB rat A 116
– GLP-1 (7–36 amide), effect of A 118
– *Helicobacter pylori* and A 184
– xylose meal A 184
Gastrin – releasing peptide – islet, effect on A 22
Gelatinase – renal – streptozotocin-diabetic rat 567
Gene – expression – control A 75
– – islet B-cell A 81
– mitochondrial – diabetes – Japan 504
– – diabetes, Type 2 372, A 17, A 28
– – mutation – insulin secretion abnormal 818
– – – MIDD 842 c
– promoter A 100
– Reg/pancreatic stone protein – expression after pancreatectomy 994
– tumour necrosis factor – diabetes – Type 1 500
Genetics *[see also* Family study, HLA, Inheritance, Polymorphism*]*
– diabetes – homogeneous affected populations, importance of 639 c
– – Type 1 A 84
– – – chromosome 6 p *vs* 2q A 6
– – – ethnic variation 739
– – – HLA – Class I 937
– – – – Class II 739, 808
– – – insulin gene 739, A 5
– – – – Japan 210
– – – interferon-γ polymorphism 1159
– – – tumour necrosis factor 937
– – – tumour necrosis factor & HLA-DR3 500
– – Type 2 959 r, A 28, A 85, A 87
– – – glucagon receptor mutation A 16
– – – glucokinase gene 182, A 17
– – – GLUT-2 420
– – – glycogen synthase gene 536
– – – mitochondrial gene 372, 818
– – – multifactorial model 1221, 1231
– – – protein phosphatase-1 G-subunit expression A 16
– diabetic nephropathy – N-acetyltransferase gene? A 191
– impaired glucose tolerance – mitochondrial gene mutation 818
– MODY – GLP-1 receptor 721
– peripheral vascular disease – diabetes A 203
– segregation analysis in Type 2 diabetes – England 1231
– – South India 1221
Gestational DM *[see* Diabetes – gest'l; Glucose – tolerance . . .; Pregnancy*]*
GIP (Glucose-dependent insulinotropic peptide)
GIP/GLP-1 hybrid peptide – insulin-secreting cell binding A 49
Glaucoma – diabetes, in A 206
Glomerular – basement membrane – diabetes – glycaemic control 483
– – diabetic nephropathy 313
– – – experimental A 35
– – thickening – heparin, protection by A 14
– filtration rate – Cockroft-Gault formula – diabetic nephropathy, in 708
– – – obese NIDDM women A 189
– – diabetic nephropathy progression 511, 604
– – measurement – ^{51}Cr-EDTA – sampling protocol A 189
– – prorenin and – Type 1 diabetes A 4
– – tuboglomerular feedback control – diabetes A 191
– hyperfiltration – ACE inhibition, effect of – kinin role A 187
– – diabetes – Type 1 A 188
– – osmotic diuresis, induced by – rat 225
– – prospective study – diabetes – Type 2 A 15
– – prostaglandin role A 190
– mesangial – cell – hepatocyte growth factor secretion 533
– – – protein kinase C – glucose, effect of 838
– – matrix – diabetic nephropathy A 35
– mesangium – diabetes – glycaemic control 483
– selectivity – Type 2 diabetes 195
– stereology 483
GLP (Glucagon – like peptide) A 118
– 1 A 49
– – (7–36 amide) – glycogenesis, effect on – skeletal muscle – rat 1163
– – – insulin-like effect – liver A 50
– – – – skeletal muscle A 50
– – – therapeutic effects A 72
– receptor – gene – MODY 721
Glucagon – diabetes, role in – streptozotocin-diabetic rat 985
– hyperinsulinaemia, effect of – rat A 46
– immunoneutralisation – streptozotocin-diabetic rat 985
– lipolytic effect A 129
– secretion – GLP-1 (7–36 amide), effect of – rat A-cell A 49
– sensitivity A 127
Glucagon-like peptide *[see* GLP*]*
Glucocorticoid – islet B-cell function, effect on A 212
– – IGF-I, effect of A 41
Glucokinase – deficiency – hepatic glycogen synthesis A 131
– gene – gestational diabetes 104, A 17
– – molecular scanning 104
– – molecular screening – Type 2 diabetes 182
– – promoter A 75, A 101
– – regulation – islet B-cell *vs* liver A 123
– – Type 2 diabetes, role in S 36
– islet B-cell – glucoreceptor? 442 c
– regulation S 43
Gluconeogenesis – hepatic glucose production, role in 697
– measurement – ^{13}C enrichment 517
– precursor – alanine *vs* glutamine – human A 127
Glucosaminyl N-deacetylase – neutrophil – glycaemic control, effect of A 3
Glucose – 6-phosphatase A 134–A 135
– – inhibitors A 134
– 6-phosphate – insulin resistance 127
– blood – analyser – Hemocue Glucose A 158
– – monitoring – sc glucose sensor compared A 170
– disposal – diabetes – Type 1 – insulin-independent A 135
– – measurement – insulin suppression test 843 c
– – non-esterified fatty acids, effect of 202
– fatty acid cycle S 155
– islet B-cell culture, effect on 15
– kinetics – Type 2 diabetes 217 r
– metabolism – sex differences 757
– oxidation – regulation S 155
– – Type 2 diabetes, reduced in A 130
– production, hepatic A 133–A 134
– – post-absorptive 697
– – tracer methods 217 r
– – Type 2 diabetes, role in 217 r
– retinal pericyte, effect on 36
– subcutaneous – monitoring *[see also* Glucose – sensor*]* 540 c
– sensor *EASD News Section: 6/94 23 w, 8/94 33 w*
– – infra-red spectral analysis – clinical use A 169
– – Nafion membrane 610
– – paracetamol (acetaminophen), insensitive to 610
– – subcutaneous – microdialysis A 170
– – – – exercise, effect of A 169
– – – sensitivity drift A 170
– tolerance – enhanced – neonatal capsaicin, following A 43
– – gestational diabetes, following A 173
– – impaired S 162
– – – ethnic differences – London 765
– – – GLP-1 (7–36 amide) release A 118
– – – hypertriglyceridaemia, in 889
– – – insulin resistance, role of – Japanese 897

– – – insulin response in A 74
– – – islet B-cell – Ca^{2+} oscillation 1121
– – – Japanese-Americans 524
– – – natural history A 26
– – – progression to diabetes – HbA_{1c} predicting 252
– – – skin blood flow 214
– – test – IV – prediabetes Type 1 388
– – – – prediction of Type 1 diabetes 365
– – – – sham feeding, effect on A 160
– toxicity – endothelial cell 264
– tracer – ^{13}C-glucose – glycogen kinetics 517
– – ^{3}H 3-o-methylglucose – transport 826
– transport A 123–A 125
– – glucose homeostasis, role in – GLUT-4 transgenic mouse 1097
– – measurement – ^{3}[H] 3-o-methylglucose 826
– – skeletal muscle – metformin, effect of 826
– – – Type 2 diabetes 270
– transporter *[see* GLUT*]*
– turnover – hemipancreatectomy, following 1036
– uptake – cerebral – *fa/fa* rat S 169
– – GLUT-4, human, effect of – transgenic mouse 1097
– – hexosamine flux, effect of A 151
– – phlorizin, effect of – rat 976
– – pregnancy, effect of – rat 976
– – skeletal muscle – C-peptide, effect of S 99
– – – hyperglycaemia, effect of A 131
– – – Type 2 diabetes, role in 217 r
– – splanchnic A 126
GLUT (Glucose transporter) A 123–A 125
– 1 – erythrocyte – stability 730 c
– – expression – glucose, effect of 443
– – perineurial – *fa/fa* rat 443
– – skeletal muscle – *fa/fa* rat 443
– 2 – expression – Type 2 diabetes S 36
– – gene – diabetes – Type 2 420
– – islet – fetal rat 134
– – islet B-cell – BB rat – Kilham rat virus, unaffected by 1186
– – – streptozotocin, effect of – mouse A 82
– 4 – expression – adipose tissue *vs* skeletal muscle A 124
– – – insulin, effect of – Type 2 diabetic families 401
– – insulin sensitivity, effect on – human GLUT-4 transgenic mouse - 1097
– – translocation A 59
– – – insulin-induced 3
– gene – promoter – transactivation by transcription factor SP1 A 81
– Zucker rat 3
Glutamic acid – decarboxylase – expression – islet B-cell – surface A 92
– – human recombinant 344
– – immune response to A 93
– – isoforms 344, S 73
– – nerve – autonomic A 73
– ester – insulin secretion, effect on A 109
– – – diabetic rat A 113
Glutathione *[see also* Oxidative stress; Oxygen – free radicals; Platelet*]*
– redox cycle – endothelial cell – high glucose, effect of 264
Glycaemic control of diabetes – albumin excretion rate progression, effect on A 195
– albumin excretion rate, effect on A 15
– albuminuria progression, effect on 1251
– cholesterol synthesis, effect on A 148
– complications of diabetes and 1172 r
– diabetes – Type 1 – complications – EURODIAB 278
– diabetic nephropathy progression, effect on 483, 1251
– diabetic retinopathy development and A 36
– gastric motility, effect on 543 r
– intraperitoneal insulin infusion S 108
– islet transplantation, following – animal diabetes A 217
– laminin, serum, effect on A 189
– left ventricular hypertrophy and – hypertensive NIDDM A 157
– microalbuminuria, effect on 441 c
– microangiopathy and – Bangladesh A 207
– monitoring *[see also* Glucose – blood; Glucose – sc*]*
– – blood glucose & urine glucose compared 170
– – Eastern Europe 332 c
– – Moscow 170
– mortality and A 156
– nerve function, effect on 579
– poor – cognitive function A 175
– tight – clinical implications 1172 r
Glycation A 68
– advanced end-product – capillary permeability preceding A 148
– – inhibitor – aminoguanidine 10
– – retinopathy, role in 32
– aminosugar autoxidation following – role in diabetic complications? A 150
– ascorbic acid, inhibition by – streptozotocin-diabetic rat 731 c
– inhibitor – D-lysine – toxicity 440 c
– products *[see also* Glycation – advanced end-product*]* 145
– – DNA, effect on 145
Glyceraldehyde – crystalline lens – streptozotocin-diabetic rat A 209
Glycerol phosphate shuttle – islet B-cell – GK rat 1082
Glycerophosphate dehydrogenase – FAD *[see* FAD. . .*]*
Glycogen – hepatic – kinetics – ^{13}C enrichment method 517
– synthase – activation – insulin-stimulated protein kinase 1 A 17
– – gene – diabetes – Type 2 – Japan 536
– – GLP-1 (7–36 amide), effect of – skeletal muscle – rat 1163
– – insulin, effect of – GK Wistar rat 885
– – non-esterified fatty acids, effect of 202
– – *Psammomys obesus* 671
– – skeletal muscle – insulin treatment, effect of 82
– – – rhesus monkey 127
Glycogenolysis – hepatic glucose production, role in 697
Glycolipid – composition – pancreas A 95
– sulphatide – tissue distribution 1000
Glycolysis – regulation S 43
Glycosaminoglycan – artery – diabetes – human 286
– diabetic microangiopathy, effect in A 198
Growth – childhood – diabetes – Type 1 925
– childhood – diabetes – Type 1 – glycaemic control A 18
– factor – hepatocyte – mesangial cell, secretion by – glucose effect 533
– – insulin-like *[see* IGF*]*
– – pancreas 994
– – platelet-derived – immunoassay 1142
– – – serum – diabetes 1142
– – transforming – β_1 – mesangial matrix, glucose effect on A 35
– – – islet B-cell protection – interleukin 1 effect A 44
– – – vitreous – diabetic retinopathy A 36
– fetal – impaired – subsequent insulin resistance 150, 624
– – insulin secretion in adult life and 592
– hormone – diabetes 224 b
– – islet B-cell culture, effect on 15
– – islet B-cell, effect on A 32
– – response – non-esterified fatty acids, effect of A 119
– – secretion – obesity – proinsulin, role of A 120
– infancy – breast-feeding and 91

H

Halban, P – Minkowski Award 1990 S 65
Hales, C N – Minkowski Award 1971 S 162
Häring, H-U – Minkowski Award 1989 S 149
HbA_1, HbA_{1c} – progression to diabetes, prediction of 252
Heart *[see also* Neuropathy – autonomic; Echocardiogram; Electrocardiogram*]*
– coronary disease *[see also* Macrovascular disease; Myocardial infarction*]*
– – diabetes A 200–A 203
– – insulin resistance and – Type 2 diabetes 597
– – risk – diabetes – Type 1 A 143
– – screening – diabetes A 201
– diabetes – sudden cardiac death – microalbuminuria 788
– function – diabetes A 185–A 187
– glimepiride, effect of A 163
– insulin resistance – *fa/fa* rat – GLUT translocation A 124
– myocardial scintigraphy A 201
– rate – variability 788
Heat stress – response – islet – BB rat A 99
Helicobacter pylori A 184
Hellman, B – Minkowski Award 1969 S 11
Heparan sulphate – glomerular basement membrane – diabetic nephropathy 313
– proteoglycan 313
– synthesis *[see also* Glucosaminyl N-deacetylase*]*
Hepatocyte – culture S 155
Hepp, K D – Minkowski Award 1976 S 108
Herbal medicines – antidiabetic A 213
Heritability – diabetes – Type 2 – South India 1221
Histamine – H_2 receptor antagonist – cimetidine – insulin secretion, effect on A 111
History – insulin, discovery of 641 b
HIT cell *[see* Insulin – secreting cell – HIT*]*

HLA – Class I – diabetes – Type 1 – Finland 937
– Class II – diabetes, Type 1 808
– – – ethnic variation 739
– – – Finland 937
– – – haplotype inheritance, maternal *vs* paternal 1105
– – DQ – diabetes – Type 2 A87
– – – endogenous retroviral homology – Type 1 diabetes A5
– – – heterodimer – Type 1 diabetes 808
– – DR – chronic pancreatitis and 471
– – – Type 1 diabetes – CD45 T-cell isoforms 155
– – polymerase chain reaction 808
– diabetes, Type 1 S73
– – Russia A84
– disease association – control group selection 845c
– haplotype inheritance – diabetes – Type 1 1105
HMG-CoA reductase inhibitor – microalbuminuria, effect on A193
Howell, S L – Minkowski Award 1983 S30
Hutton, J C – Minkowski Award 1988 S48
Hyaluronic acid – artery – human aorta – diabetes 286
Hygiene – Type 1 diabetes incidence, role in? 729c
Hyperaemia *[see* Blood – flow – skin*]*
Hyperandrogenism – treatment – flutamide – hyperinsulinism, effect on A63
Hypercholesterolaemia – insulin resistance A137
Hyperglycaemia – acute – nerve function, effect on – human 1216
– hypoglycaemia awareness, effect on A166
– insulin receptor, effect on S149
Hyperinsulinaemia A135–A141
– adrenaline production, effect on – euglycaemic man A132
– assay method, importance of 945r
– cardiovascular risk factor 953r
– childhood – risk factor for Type 2 diabetes 617
– chronic – insulin sensitivity, effect on – skeletal muscle A136
– – lipid profile, effect on – rat A67
– cognitive function – elderly A175
– *db/db* mouse 739
– insulin resistance following S169
– insulin resistance syndrome, in 945r, 948r
– insulin secretion, effect on 1025
– neonatal – New Zealand 930
– vascular reactivity, effect on A142, A19
Hyperlipidaemia – treatment *[see also* Hypolipidaemic agent*]*
Hypertension – essential – amylin secretion 188
– – diabetes A45
– – – angiotensin converting enzyme inhibitor 300
– – – ACE inhibitor 511
– – – diabetes treatment, effect of A144
– – atrial natriuretic peptide, effect of 308
– – glucose tolerance in A143
– – insulin resistance in – glucose sensitivity, role of A137
– – – amylin role? A116
– – – skeletal muscle *vs* heart A139
– – microalbuminuria and – diabetes – Type 1 1015
– – pathogenesis – insulin resistance A138
– – salt sensitivity – insulin, role of 308
– treatment – ACE inhibitor *vs* β-blocker – diabetes – Type 2 A144
– – diabetic foot, effect on A204
– – diabetes – Type 2 A195
– – insulin sensitivity, effect on A140
– – intensive – diabetes – Type 2 A143
Hypertriglyceridaemia – *Ficus carica* leaf, effect of – diabetic rat A213
– glucose tolerance abnormality in – mechanism 889
– non-esterified fatty acid suppression in 889
– postprandial – lipid tolerance testing A146
– renal effect, lack of A191
Hypoglycaemia 1170b, A46, A165–A167
– awareness A165
– – childhood diabetes A19
– – posture, effect of 1241
– cerebral blood flow, effect on 257
– childhood diabetes 70
– cognitive function, effect on 643r, 797
– counterregulation – insulin, effect of 797
– – intensive insulin therapy 1265
– – islet function – NAME, effect of A112
– – sex, effect of 797
– insulin-induced – intraperitoneal *vs* peripheral route A66
– postural responses, effect on – Type 1 diabetes 1241
– sympathoadrenergic response – liver glucosensor in A47
– thermoregulation, effect on 689
– treatment – oral glucose – time-course of effect A165
– Type 1 diabetes – EURODIAB study 278
– unawareness A47
– – reversibility – Type 1 diabetes 1265
Hypoglycaemic agent *[see also* Adrenoceptor – α_2 – blocking agent*]* A162, A163
– A4166 A210
– AG-EE 623 ZW 703
– α_2-adrenergic blocking agent *[see* Adrenoceptor*]*
– BRLP-42 – diabetic neuropathy, effect on A73
– – gene expression, effects on A210
– – retinopathy, protection against A37
– – vascular reactivity, effect on A7
– characterisation – euglycaemic clamp study 703
– GLP-1 – β-adrenergic blockade, safe in A119
– GR92132X – diabetes – Type 2 A209
– herbal A213
– MCHP (2-(3-methyleinnamylhydrazono)-proprionate) A125
– metformin *[see* Metformin*]*
– oral – CS-045 A63
– PPIB (2-(3-phenylpropoxyimino)-butyrate) A125
– secondary failure A163
– succibun – oxygen free radical scavenger A210
– sulphonylurea *[see* Sulphonylurea*]*
– thioctic acid – glucose uptake, effect on A125
– sitostanol ester 773
Hypothermia *[see* Thermoregulation*]*

I

IAPP (Islet amyloid polypeptide; Islet-associated polypeptide) *[see* Amylin*]*
ICAC *[see* Adhesion molecule – intercellular*]*
IGF-I – diabetes 224b
– erythropoiesis, effect on 439c
– expression – tissue distribution – streptozotocin-diabetic rat 1073
– insulin sensitivity, effect on A40
– islet B-cell function, inhibition of – conscious rat A119
– pregnancy – diabetes A173
– receptor S125, S135
– – mutant – binding, effect on A123
– recombinant human – metabolic effects S179
– skeletal muscle, effect on – GLUT-4 translocation A40
– therapeutic potential – Type 2 diabetes S179
– treatment – non-esterified fatty acid utilisation increased A120
IGF binding protein – 3 – glycation, effect of A150
– – IGF-I binding kinetics – biosensor A41
– expression – nutritional factors A41
Imidazoline – receptor – ligand – insulin secretion, effect on A110
Immune response – diabetes – Type 1 – hepatitis B vaccine A64
Immunocytochemistry – intestine – insulin absorption 119
Immunogenicity – insulin – analogue 1178
Immunotherapy – animal diabetes *[see* Mouse – NOD; Rat – BB*]*
– Type 1 diabetes *[see* Diabetes – Type 1 – remission induction*]*
Impaired glucose tolerance *[see* Glucose – tolerance – impaired*]*
Impotence – diabetes – pathogenesis A178
– nocturnal tumescence studies 335c
Infection – diabetes, in – hepatitis C A157
– resistance to *[see also* Neutrophil, polymorphonuclear; Macrophage*]*
Inheritance – maternal – diabetes – mitochondrial gene 504
– nitroso-induced glucose intolerance – betel nut 49
Instructions for Authors *Advertisement pages, Jan & July issues*
Insulin – absorption – intestinal 119
– – sc 377
– analogue – fast-acting 713
– – HOE71GT *[see* – – slow-acting – Gly(A21)-Arg_2(B31,B32)*]*
– – immunogenicity – transgenic mouse, evaluation in 1178
– – lispro *[see* Insulin – analogue – monomeric – Lys(B28),Pro(B29)*]*
– – monomeric – Lys(B28),Pro(B29) 713, A167–A169
– – – – VLDL composition effect A147, A168

– – – – zinc A78
– – slow-acting – Gly(A21)-Arg_2(B31,B32) A78, A169
– antibodies – glycaemic control – pregnancy A58
– assay – enzymimmunometric A158
– autoantibodies – diabetes – Type 1 S73
– – prediction of Type 1 diabetes A89
– conformation – antibody, effect of – insulin receptor binding, effect on A121
– discovery 641b
– gene – diabetes – Type 1 – ethnic variation 739
– – diabetes – Type 1 – Japan 210
– – expression – amylin, effect of A115
– – – HIT-T15 cell – insulin, regulation by 559
– – promoter A100
– – regulation A75, S3
– immunogenicity – Lys(B28),Pro(B29) insulin A167
– – transgenic mouse, evaluation in 1178
– infusion – device S108
– – – implantable A65, *EASD News Section: 6/94 23w, 8/94 33w*
– – intraperitoneal A65
– – sc – Type 1 diabetes – insulin sensitivity, effect on A141
– intranasal A164
– *EASD News Section: 6/94 23w, 8/94 33w*
– intraperitoneal S108
– – growth hormone sensitivity, effect on A41
– mRNA – streptozotocin-diabetic rat – neonatal 351
– oral A164
– – intestinal absorption – rat 119
– platelet function, effect on 632
– preparation – concentration – absorption, sc, effect on 377
(Insulin) – receptor 1288b
– – signalling – pH A31
– – down-regulation – *db/db* mouse 739
– – gene – mutation A29
– – glucose, high, effect of A9
– – internalisation S117
– – isoforms A121
– – – hyperinsulinaemia, chronic, effect of A9
– – Lys(B28),Pro(B29) insulin treatment, effect of A167
– – mutant – binding, effect on A123
– – – tyrosine kinase deficient – transgenic mouse A10
– – negative co-operativity S135
– – phosphorylation S125
– – phosphotyrosine phosphatase assay 56
– – signalling *[see also* Insulin – receptor – substrate-1*]* A121–A123, S149
– – – *fa/fa* rat, impaired in A10
– – – IRS-1, independent of A30
– – – mitogen-activated protein kinase A31
– – – – ageing A121
– – – phosphatidyl-inositol 3'-kinase, role of A30, A31
– – structure S135
– – substrate-1 – deficiency A30
– – – gene – diabetes – Type 2 A29
– – – polymorphism – diabetes – Type 2 A86
– – – recombinant human A30
– – tyrosine kinase S125
– – – diabetic *vs* non-diabetic muscle A9
– – – glucose inhibition – site A122
– – – tumour necrosis factor, inhibition by A9
(Insulin) – release *[see* B-cell, islet; Insulin – secretion; Insulin – secreting cell; Islet*]*
– resistance *[see also* GLUT; Glucose – uptake; Glycogen – synthase; Insulin – sensitivity*]* 1288b, A135-A141
– – amylin secretion 188
– – birth-weight preceding – thinness 150, 624
– – blood flow, role of A20
– – cAMP-induced – adipocyte A123
– – cardiovascular risk factor 597
– – chronic hyperinsulinaemia, induced by 1025
– – diabetes – Type 2 – hepatic *vs* peripheral A136
– – elderly A183
– – *fa/fa* rat S169
– – fatty acid, role of S155
– – glucocorticoid-induced – glucose-fatty acid cycle S169
– – – relatives of Type 2 diabetes A85
– – glycogen synthase in – rhesus monkey 127
– – hypertension and 308
– – impaired glucose tolerance, role in – Japanese 897
– – insulin receptor – internalisation and S117
– – – substrate-1 gene A29
– – – tyrosine kinase activity A10
– – liver – Type 2 diabetes 217r
– – measurement – insulin suppression test 843c
– – obesity, induced by – neuropeptide Y treated rat 1202
– – phosphotyrosine phosphatase, role of 56
– – rat – ageing Sprague-Dawley 969
– – relatives of Type 2 diabetics – physical inactivity role A28
– – skeletal muscle – Type 2 diabetes – reversibility 270
– – stress-induced 247
– – subcutaneous – Lys(B28),Pro(B29) insulin, use of A168
– – substrate – 1 – gene – diabetes – Type 2 A17
– – syndrome 945r
– – – amylin and A116
– – – animal model – lipid peroxidation A137
– – – hyperinsulinaemia in 945r, 948r
– – – Japanese 897
– – – Japanese-Americans 524
– – treatment – S15261 969
(Insulin) – secreting cell *[see also* B-cell, pancreatic Islet*]*
– – Ca^{2+} – carbachol, stimulation by A32
– – CD14 expression A97
– – cytokine, effect of – DNA fragmentation 733
– – G-protein, role of A32
– – GLUT-2 – gene – promoter A100
– – HIT – insulin gene expression – long-term 559
– – INS-1 A100
– – streptozotocin toxicity – GLUT-2 and A114
(Insulin) – secretion *[see also* B-cell, islet; Insulin – secreting cell; Islet*]* A11, A32, A108–A112
– – acarbose, effect of A108
– – acetyl choline, effect of S112
– – amylin antagonist, effect of – $_{8-32}$ salmon calcitonin A116
– – amylin overexpression, effect of – transgenic mouse 725
– – caffeine, effect of S112
– – chronic hyperglycaemia, effect of 1025
– – chronic hyperinsulinaemia, effect of 1025
– – D-glyceraldehyde, stimulation by A12
– – fetal – GLUT-2, role of 134
– – galanin, effect of A21
– – GK Wistar rat 863, 1082, A42
– – glucose potentiation – nervous control and A114
– – glucose, regulation by S11
– – granule – biogenesis S48
– – hypertriglyceridaemia, in 889
– – hypoglycaemia, suppression by 797
– – islet B-cell heterogeneity and S57
– – *Momordica charantia*, effect of A213
– – nervous control A110, A114
– – nitric oxide, role of 879
– – noradrenaline, inhibition by – pertussis toxin sensitive A21
– – pathways S65
– – peptide YY, effect of 871
– – pre-hepatic – measurement A126
– – previous fetal growth and 592
– – protein kinase, role of S21
– – pulsatility S11
– – – diabetes – Type 2 A112
– – – – – animal model aA113
– – – islet B-cell cytoplasmic Ca^{2+} oscillation and A69
– – rate – combined model method A108
– – second messengers, role of S30
– – streptozotocin-diabetic rat – neonatal 351
– – succinic acid esters, stimulation by S36
– – verapamil, stimulation by S112
(Insulin) – sensitivity – amylin, effect of 166
– – angiotensin converting enzyme inhibitors, effect of 300
– – bradykinin, effect of 300
– – fatty acid composition and 1044
– – GLUT-4, human, effect of – transgenic mouse 1097
– – hemipancreatectomy, following 1036
– – IGF-I, effect of S179
– – measurement A126
– – minimal model assessment 1036
– – non-esterified fatty acids, effect of 202
– – sex and A136
– – systemic pancreatic venous drainage, effect of A151
– suppression test – octreotide used in 843c
– treatment, intensive 1172r, A65
– – diabetic nephropathy progression A196
– – Eastern Europe 332c

– – hypoglycaemia in A 167
– – – avoidance of 1265
– – – childhood A 19
– – Moscow 170
– – nocturnal glycaemia A 47
– – retinal function and 911
Insulitis – calcitriol, effect of – NOD mouse 552
– $CD8^+$ cell involvement – TNF-α-expressing transgenic mouse 1277
– cytokine mRNA – NOD mouse 833
– diabetes – Type 1 S 82
– imaging in vivo – radiolabelled immunoglobulin A 91
– macrophage involvement – BB rat 466
– nitric oxide synthase expression – NOD mouse 1154
– oxygen free radicals in – NOD mouse 22
– tumour necrosis factor in – transgenic mouse 1277
Interferon-γ – gene – polymorphism – Type 1 diabetes 1159
– insulin-secreting cell, effect on 733
Interleukin – 1 – insulin secretion, inhibition of – interleukin 10 synergism A 96
– – insulin-secreting cell, effect on 733
– – islet cytotoxicity – arachidonic acid metabolism A 113
– – – aurothioglucose protection A 43
– – receptor antagonist – endogenous – Type 1 diabetes A 96
– – – streptozotocin-diabetes prevention A 93
– – Type 1 diabetes, role in pathogenesis *EASD News Section 10/94 42*
– 2 – diabetes – Type 1 476
– – receptor – gene – diabetes – Type 1 A 6
– 4 – diabetes – Type 1 476
International Diabetes Epidemiology Group *EASD News Section 7/94* 28 w
Intestine – cholesterol metabolism, role in – diabetes A 66
– insulin absorption 119
– lymph – chylomicron preparation – streptozotocin-diabetic rat 238
– motility *[see* Diarrhoea*]*
Ion flux – islet B-cell *[see* B-cell, islet – Ca^{2+}; B-cell, islet – K^+ *]*
– Na^+ *[see* Sodium – transport*]*
IRS-1 *[see* Insulin – receptor – substrate-1*]*
Islet – autoantigen S 90
– blood flow – diabetic rat 677
– Ca^{2+} – oscillation – culture factors affecting 1007
– – peptide YY, lack of effect of 871
– cAMP – neonatal streptozotocin-diabetic rat A 115
– – peptide YY, effect of – mouse 871
– cell – cytotoxicity – FITC binding, protection by A 77
– cholecystokinin, effect of – G-protein role A 32
– culture – C^{2+} oscillation, effect on 1007
– denervation S 112
– diabetes – Type 2 – FAD-glycerophosphate dehydrogenase 177
– EASD Study Group *EASD News Section 7/94 27 w*
– FAD-glycerophosphate dehydrogenase 177
– G-protein A 33
– glucose metabolism – diabetes – Type 2 177
– K^+ channel – peptide YY, lack of effect of 871
– perifused – GK Wistar rat 863
– protein kinase C – peptide YY, lack of effect of 871
– sulphatide 1000
– toxicity – heat shock, protection by A 53
– virus, effect of 222 c
Italy – Microalbuminuria Study 1015

J

Japanese-Americans – impaired glucose tolerance 524
Jeanrenaud, B – Minkowski Award 1970 S 169
Juntti-Berggren, Lisa – Albert Renold Fellowship 1994 *EASD News Section 10/94 45*

K

Ketoacidosis, diabetic – presentation of diabetes 70
– prevention 332 c
Ketosis – Type 1 diabetes – EURODIAB study 278
Kidney – sulphatide 1000
Kilham rat virus 1186

L

Lactate – glucose production, effect on – liver A 133
– metabolism – amylin, effect of A 117
– skin, release in – human A 128
Laminin – $_{P1}$ – platelet activation, role in? – diabetes A 208
Lernmark, A – Minkowski Award 1984 S 73
Leucocyte – mononuclear (see Lymphocyte; Macrophage*]*
– neutrophil – hypoglycaemia, effect of A 166
– – superoxide production – diabetes, impaired in A 14
Lewis blood group *[see* Blood – group – Lewis*]*
Life-table analysis – diabetes – Type 1 – families 321
Limited joint mobility *[see* Cheiroarthropathy*]*
Linomide – NOD mouse, prevention of diabetes in 1195
Lipase – adipose tissue – pregnancy, effect of – rat A 171
Lipid – lowering agent *[see* Hypolipidaemic agent*]*
– peroxides – serum – measurement A 146
Lipoatrophy – congenital – insulin receptor signalling defect A 10
Lipogenesis – vanadate, effect of – streptozotocin-diabetic rat 1065
Lipoic acid *[see* Anti-oxidant*]*
Lipolysis – Lys(B28),Pro(B29) insulin, effect of A 168
– non-esterified fatty acids, regulation by 202
Lipoprotein *[see also* Apolipoprotein, Cholesterol, Chylomicron, Lipid, Triglyceride*]*
– (a) – albumin excretion rate and – diabetes – Type 1 A 195
– – coronary heart disease and – diabetes – Type 2 585
– – diabetes A 66
– – – diabetes treatment, effect of A 144
– – – relatives, in A 145
– – insulin resistance and – diabetes – Type 2 A 138
– apo – B48 – chylomicron clearance 238
– glucose disposal, effect on 202
– IGF-I, effect of S 179
– intestinal metabolism – diabetes – Type 2 1259
– kinetics – sitostanol, effect of 773
– LDL *[see also* Lipoprotein – (a)*]* – acetate ingestion, effect of A 129
– – glycosylation – diabetes A 67
– – lymphocytes & monocytes, uptake by A 129
– – small dense 681
– – subclasses – diabetic nephropathy 681
– profile – microalbuminuria, in – diabetes – Type 2 A 195
– serum – ethnic differences – Afro-Caribbean *vs* European 765
– – insulin response and A 146
– – intestinal origin – glipizide, effect of 781
– – sex differences 757
– – Sf >400 781
– – Sf 20–400 781
– triglyceride-rich – postprandial – diabetes – Type 2 1259
– VLDL – composition – Lys(B28),Pro(B29) insulin treatment A 147, A 168
Lung – function – diabetes A 149
Lymphocyte – subsets – children of diabetic mothers 1132
– – $CD4^+$ – NOD mouse 337
– – $CD8^+$ – activation – Type 1 diabetes A 63
– – – insulitis, role in – TNF transgenic mouse 1277
– – CD95 (Fas/Apo-1 antigen) – Type 1 diabetes A 90
– – cloning A 98
– – GAD 65 recognition – dominant epitopes A 89
– – helper – subtypes – NOD mouse insulitis 1154
– – interleukin-2, effect of – Type 1 diabetes 476
– – memory 155
– – proliferation – modified adhesion molecule, inhibition by A 83
– – regulatory – NOD mouse 337
– – suppressor – NOD mouse – calcitriol, effect of 552
– – Type 1 diabetes – CD45 isoforms 155
Lysine – D- – glycation inhibitor – toxicity 440 c

M

Macaca mulatta - diabetes 127
– glucose disposal – skeletal muscle 127
Macleod, JJR – biography 641b
Macroangiopathy – diabetes – microangiopathy, effect of A203
– marker – elastin peptides A202
Macrophage – insulitis, involvement in – BB rat 466
– – NOD mouse 22
– marker – biopterin 466
Macrovascular disease *[see also* Heart – coronary dis.; Vascular – dis.*]*
– diabetes prevalence in A157
Magnesium, serum – Type 1 diabetes – (micro) albuminuria, unrelated to 639c
Major Histocompatibility Complex *[see* MHC; HLA*]*
Malaisse, W J – Minkowski Award 1972 S36
Mandrup-Poulsen, Thomas – Minkowski Lecturer 1994 *EASD News Section 10/94 42*
MAPK *[see* Insulin – receptor – signalling – mitogen-activated protein kinase*]*
Martin, JM – obituary *EASD News Section 6/94 21*
Mass spectrometry – matrix assisted laser desorption ionisation A68
Maternally-inherited diabetes with deafness (MIDD) – non-isotopic diagnosis 842 c
– Netherlands 1169c
MCHP *[see* Hypoglycaemic agent – MCHP*]*
MELAS (Mitochondrial encephalomyopathy, lactic acidosis & stroke-like episodes)
– islet B-cell function impaired 818
Mesangial *[see* Glomerular*]*
Metabolism – studies in vivo A126–A133
Metformin – cardiovascular risk factors, effect on A200
– glucose transport, effect on – drug concentration and 826
– hepatocyte, effect on – albumin synthesis increased A163
– metabolic effects A62
Metoclopramide – vagal neuropathy, test for A184
MHC (Major Histocompatibility Complex) *[see also* HLA*]*
– expression – islet B-cell A83
Microalbuminuria A192–A196
– autonomic function – Type 1 diabetes 788
– capillary permeability, peripheral – diabetes – Type 2 A16
– cardiovascular risk factor – sialic acid, role of A13
– diabetes – Bangladesh A192
– – glomerular selectivity 195
– – – hypertension and 1015
– – – Italy 1015
– – – nerve function 1056
– glycaemic control, effect of 441c
– hypertension – diabetes – renal function prediction A45
– LDL subclasses – diabetes – Type 1 681
– low-molecular-weight heparin, effect of A188
– magnesium, serum 639c
– pregnancy, effect of – Type 1 diabetes 905
– progression – diabetes – childhood A193
– – glycaemic control, effect of 483
– – pregnancy, in – Type 1 diabetes 905
– risk factors for – childhood diabetes A18
– sodium transport and A190
Microangiopathy *[see also* Blood – flow*]*
– diabetes – macroangiopathy, effect of A203
– diabetic neuropathy, role in 847r
– prediction – haemorheology – DCCT A25
Microencapsulation – islet A215–A217
MIDD *[see* Maternally-inherited diabetes with deafness*]*
Minkowski Award – 1966: Randle, P J S155
– 1967: Froesch, E R S179
– 1969: Hellman, B S11
– 1970: Jeanrenaud, B S169
– 1971: Hales, C N S162
– 1972: Malaisse, W J S36
– 1974: Cerasi, E S3
– 1975: Freychet, P F S186
– 1976: Hepp, K D S108
– 1977: Wahren, J S99
– 1978: Nerup, J S82
– 1979: Ashcroft, S J H S21
– 1980: Täljedal I-B S112
– 1981: De Meyts, P S135
– 1983: Howell, S L S30
– 1984: Lernmark, Å S73
– 1985: Van Obberghen, E S125
– 1986: Pipeleers, D S57
– 1987: Carpentier, J-L S117
– 1988: Hutton, JC S48
– 1989: Häring, H-U S149
– 1990: Halban, P S65
– 1991: Boitard, C S90
– 1992: Van Schaftigen, E S43
– 1994: Mandrup-Poulsen, Thomas *EASD News Section 10/94 42*
– Symposium – Introduction S1
– – Summary S187
Mitochondrion, Mitochondrial – diabetes – insulin secretion defect A28
– – Japan 504
– encephalomyopathy, lactic acidosis, strokes *[see* MELAS*]*
– gene *[see* Gene – mitochondrial*]*
– – diabetes – Type 2 S36
– – mutant $tRNA^{Leu(UUR)}$(3242) – MELAS 818
– – – MIDD 842c
– redox state – islet – nutrient-induced changes A11
Mitogen-activated protein kinase *[see* Insulin – receptor – signalling. . .*]*
MODY (Maturity-onset diabetes in youth)
– genetics – GLP-1 receptor 721
– mitochondrial 504
Molecular biology – diabetes – Type 1 S73
Momordica charantia - insulin secretion, effect on A213
Monkey – rhesus *[see Macaca mulatta]*
Morphometry – islet 111
Mortality – cardiovascular – diabetes A201
– diabetes A152, A155
– – Type 1 – Denmark A26
– macrovascular disease – Netherlands A155
– microalbuminuria and 1287c
Mouse – alloxan-diabetic – amylin and insulin expression A115
– *db/db* – insulin resistance 739
– goldthioglucose obese – phosphotyrosine phosphatase in 56
– islet transplantation S112
– NOD (non-obese diabetic) – autoantigen S90
– – calcitriol, effect of 552
– – cyclophosphamide, diabetes acceleration by A98
– – cytokine – circulating A77
– – dihydrotestosterone, effect of A93
– – Freund's adjuvant, effect of – islet cytokine mRNA 833
– – immunology A94
– – immunomodulation – linomide 1195
– – insulin secretion – GLP-1, effect of A118
– – insulitis – oxygen free radicals in 22
– – nitric oxide synthase expression 1154
– – T-cell reactivity – GAD_{65} A92
– – T-cells – regulatory 337
– transgenic – amylin hypersecreting A51, 725
– – GLUT-4, human – insulin sensitivity 1097
– – insulin immunogenicity evaluation, use in 1178
– – tumour necrosis factor, expressing in islet B-cells 1277
Muscle – cardiac – culture S155
– skeletal *[see also* Glucose – uptake; GLUT; Glycogen; Insulin – resistance; Insulin – sensitivity*]*
– – amylin, effect of A116, A117
– – diabetes – insulin treatment, effect of 82
– – fatty acid, effect of S155
– – fructose transport A59
– – GLP-1 (7–36 amide), effect of 1163
– – – inositol-phosphoglycan role A119
– – glucose metabolism – twins A88
– – glucose transport – Type 2 diabetes – reversibility 270
– – glucose uptake – C-peptide, effect of S99
– – – Type 2 diabetes, role in 217r
– – GLUT-1 – denervation, effect of A123
– – – *fa/fa* rat 443
– – GLUT-4 – diabetes – Type 2 401
– – – translocation 3
– – glycogen synthase – insulin, effect of – GK Wistar rat 885
– – human – glucose transport – metformin effect 826
– – hypoglycaemia, effect of A46
– – insulin sensitivity – ageing A182
– – oxygenation – Type 1 diabetes A178
– – phospholipid – fatty acid composition 1044
– smooth *[see also* Vascular – reactivity*]* – non-vascular – anococcygeus – rat 233
Myo-inositol – neuropathy, in – streptozotocin-diabetic rat 651
Myocardial infarction – diabetes, new diagnosis of A201
– prognosis – diabetes A55

N

NAME (NG-nitro-L-arginine methyl ester)
– hypoglycaemia counterregulation, effect on – mouse A112
– insulin secretion, effect on 879

– – sodium nitroprusside, antagonism by A 111
Neonate – maternal diabetes – lymphocyte subsets 1132
– nutrition – cerebellar growth, effect on – IGF and – rat A 172
Nepheloepsis tuberosa – serum glucose, effect on – rat A 213
Nephropathy, diabetic A 3, A 34
– angiotensin converting enzyme inhibitor 511
– EASD Study Group *EASD News Section 11/94 53w*
– genetics – perlecan gene RFLP A 4
– glomerular basement membrane 313
– glomerular selectivity 195
– glycaemic control and – EURODIAB study 278, 483
– growth factors, role of 533
– incidence A 4
– LDL subclasses 681
– monitoring – Cockroft-Gault formula inadequate 708
– progression – ACE inhibitor – β-blocker as good 604
– – ACE inhibitor, effect of A 188
– – β-blocker delays 604
– – prediction 511
Nerup, J – Minkowski Award 1978 S 82
Nerve – blood flow – endothelin 1 antagonist, effect of 1209
– – imaging 1167c
– conduction – dog 141
– epineurial vessel photography 1167c
– function A 177–A 182
– – diabetes – glycaemic control and 579
– – – Type 1 – microalbuminuria 1056
– – endothelin 1, effect of – streptozotocin-diabetic rat 1209
– – hyperglycaemic clamp, during – human 1216
– – ketones, effect of A 181
– GLUT – 1 – *fa/fa* rat 443
– hypoxia – diabetic neuropathy, role in 847r
– ischaemia – diabetic rat 43
– NANC (non-adrenergic non-cholinergic) – streptozotocin-diabetic rat 233
– nitrergic – streptozotocin-diabetic rat 233
– non-adrenergic non-cholinergic *[see* Nerve – NANC*]*
– oxidative stress – diabetic rat A 180, 449
– redox state – glucose and hypoxia, effect of A 180
– Schwann cell – IGFPB secretion A 73
NEURODIAB (European Diabetic Neuropathy Study Group) *EASD News Section 12*
Neuropathy – autonomic, diabetic – cardiac – heart rate – spectral analysis A 185–A 186
– – – MIBG imaging A 8
– – – myocardial blood flow A 8
– – – noradrenaline sensitivity A 185
– – – SPECT A 8
– – endothelin level A 198
– – GAD antibody 293
– – gall-bladder 75
– – galvanic skin response 1051
– – gastric motility 543r
– – Gastrintestinal *[see* Diarrhoea; Gastric; Vomiting*]*
– – metoclopramide test A 184
– – microalbuminuria and 788
– – progression A 179
– – pupillary light reflex 414
– – retinopathy and A 179
– – screening 1168c
– – sleep study A 179
– – stress response in A 181
– – sulphatoxymelatonin, urinary A 79
– – transcutaneous oximetry 1051
– diabetic A 177–A 182
– – aldose reductase inhibitor *[see also* Aldose – reductase – inhibitor*]* 141, 651
– – anti-oxidant, effect of – rat 449
– – endothelin-1 involved? – streptozotocin-diabetic rat 1209
– – epineurial blood flow 1167c
– – glycaemic control – EURODIAB study 278
– – – Oslo study 579
– – histology A 79
– – IGF-I expression and – streptozotocin-diabetic rat 1073
– – ORG 2766, effect of 408
– – oxidative stress, role of 449
– – progression – renal biopsy A 15
– – screening A 204
– – – clinical score A 180
– – – pinprick perception tester A 179
– – treatment – mexiletine A 177
– – – ORG 2766 A 178
– – vascular factors 847r
– galactosaemic – aldose reductase inhibitor, effect of 141
Neuropeptide Y – intracerebral – obesity induced by – rat 1202
– intracerebral, effect of – rat S 169
Neutrophil, polymorphonuclear *[see* Leucocyte*]*
NG-nitro-L-arginine methyl ester *[see* NAME*]*
Nicotinamide – IMDIAB study A 64
– islet B-cell protection – poly (ADP-ribose)polymerase A 97
NIDDM *[see* Diabetes – Type 2*]*
Nitrate – tolerance – diabetes, impaired in 115
Nitric oxide *[see also* Vascular – reactivity*]*
– diabetic nephropathy, role in A 190
– insulin secretion, role in S 30
– insulin-secreting cell – DNA damage A 52
– – DNA synthesis, effect on A 52
– islet – interleukin-1-induced – modulation A 44
– neurotransmission – streptozotocin-diabetic rat 233
– pathway activity – nitrite, urinary – diabetic rat A 197
– synthase – blockade – insulin secretion, effect on – rat 879
– – – NAME 879
– – diabetic nephropathy risk and A 4
– – expression – insulitis – NOD mouse 1154
– – insulin-secreting cell – regulation A 52
Nitroso compounds – betel nut 49
Nutrition *[see also* Diet*]* – measurement – editorial guidelines 222c

O

Obesity S 169
– Afro-Caribbean *vs* European Londoners 765
– childhood – diabetes – Type 1 925
– hypothalamic – neuropeptide Y model 1202
– metabolic studies A 132–A 133
– neuropeptide Y, induced by – rat 1202
– non-esterified fatty acids – pulsatile A 128
– truncal – birth-weight preceding 624
– upper-body – lipolysis in 428
– visceral – exercise, effect of A 162
– – glucose homeostasis A 139
– – – rat A 150
Obituary – Martin, JM *EASD News Section 6/94 21*
Octreotide – insulin suppression test, use in 843c
Oleic acid – insulin secretion, stimulation of – protein kinase C delta in A 108
Opioid – diabetic neuropathy and A 181
ORG 2766 *[see* $ACTH_{4-9}$ – analogue; Neuropathy – diabetic*]*
Oscillation *[see also* Insulin – secretion; Islet – Ca^{2+} *]*
Oxidative stress – nerve – glucose & hypoxia, effect of A 180
Oximetry – transcutaneous – diabetic autonomic neuropathy 1051
Oxygen free radicals *[see also* Anti-oxidant; Oxidative stress; Pro-oxidant*]*
– activity – hypoglycaemia, effect of A 166
– diabetes – Type 1 S 82
– diabetic neuropathy – streptozotocin-diabetic rat 449
– endothelial cell – glucose, induced by 264
– heart – diabetes A 7
– NOD mouse insulitis, in 22
– scavenger – metallothionein A 103
– – kidney – streptozotocin-diabetic rat A 190
– – superoxide dismutase 22, A 190
– source – cytochrome P-450 A 130
– vascular thrombosis and – diabetes A 54

P

PACAP (pituitary-adenylate-cyclase-activating polypeptide)
– islet, effect on A 111
Pancreas – exocrine – secretion – hyperglycaemia, effect of A 185
– hemipancreatectomy – metabolic compensation 1036
– stone protein (PSP) – gene 994
Pancreatitis – chronic – islet autoimmunity not induced 471
Paracetamol – glucose sensor interference 610
Partial correlation – pupillary light reflex 414
Peer review – diabetes care – documentation A 176
Peptide – YY – insulin secretion, inhibition of 871
Pericyte – retinal – glucose, effect of 36
Periodontal disease – diabetes A 89

Phlorizin – glucose kinetics, effect on – rat 976
Phorbol ester – glucose uptake, effect on – adipocyte A 125
Phosphatase *[see* Protein – phosphatase*]*
Phosphatidyl-inositol 3'-kinase *[see* Insulin – receptor – signalling. . .*]*
Phosphofructokinase – skeletal muscle – insulin treatment, effect of 82
Phospholipase – A2 – insulin-secreting cell A 101
– C – regulation – insulin-secreting cell A 107
– skeletal muscle – fatty acid composition 1044
Phosphotyrosine phosphatase – assay – skeletal muscle A 122
– goldthioglucose obese mouse 56
Photoaffinity labelling – sulphonylurea receptor A 61
PI3K *[see* Insulin – receptor – signalling – phosphatidyl-inositol 3'-kinase *]*
Pima – progression to diabetes – HbA1c 252
Pipeleers, D – Minkowski Award 1986 S 57
Pituitary – adenylate-cyclase-activating polypeptide *[see* PACAP*]*
Plasminogen activator inhibitor – coronary heart disease A 54
– pregnancy – diabetes A 172
– sulphonylurea, effect of A 24
Platelet – aggregation – insulin, effect of – insulin resistance, reduced in A 139
– – taurine supplementation, effect of A 159
– – thrombin-induced – Type 2 diabetes 632
– buffering capacity – microalbuminuria, in A 196
– diabetes A 25
– diabetes treatments, different effects of 632
– glutathione – metabolism – diabetic microangiopathy and A 207
– Mg^{2+} – diabetes – Type 2 A 139
– protein phosphorylation – thrombin-induced – Type 2 diabetes 632
Polymerase chain reaction (PMR) – HLA Class II 808
Polymorphism – glycogen synthase gene – diabetes – Type 2 536
– single-strand conformation – glucokinase 104, 182
Polyol pathway *[see also* Aldose – reductase*]*
– diabetes complications, role in – phosphatidylsorbitol, membrane 1147
– sorbitol dehydrogenase – inhibitor – S-88–0773 A 206
Postural response – hypoglycaemia, effect of – Type 1 diabetes 1241
Power spectral analysis 788
PPIB *[see* Hypoglycaemic agent – PPIB*]*
Pravastatin *[see* HMG-CoA reductase inhibitor*]*
Prediabetes – BB rat – macrophage activity 466
– *db/db* mouse – hyperinsulinaemia 739
– GK Wistar rat 863
– Type 1 – endocrine autoimmunity 95
– – hyperproinsulinaemia 729c
– – polyendocrine autoimmunity 365
– – progression to diabetes 388
– – tumour necrosis factor α levels A 90
– Type 2 – neonatal hyperinsulinaemia 930
– – proinsulin, serum A 74
– – split proinsulin A 57
Prediction – diabetes – after renal transplantation A 156
– – Type 1 A 55, A 56, *EASD News Section 8/94 37 w*
– – – endocrine autoimmunity, in 95
– – – GAD antibody 917, A 89
– – – islet-cell antibodies 917
– – – polyendocrine autoimmunity 365
– – Type 2 617
– diabetic nephropathy A 192
Pregnancy *[see also* Birth, Embryo, Fetus, Neonate, Offspring, Placenta, Trophoblast*]*
– diabetes A 172–A 174
– – insulin antibodies – morbidity and A 58
– – microalbuminuria, progression of 905
– – placental lactogen A 57
– metabolic changes – feto-placental glucose steal – rat 976
– nutrition – offspring – insulin secretion in A 80
– obesity – cord blood insulin and 930
– pancreas transplantation, following A 215
Prevention – diabetes – Type 1 *EASD News Section 8/94 37 w*
Pro-oxidant – primaquine – neuropathy – rat 449
Probucol *[see* Anti-oxidant*]*
Proinsulin – conversion S 48, S 65, A 103, A 104
– assay S 162
– – intact A 103
– serum level, raised – Type 1 diabetes, preceding 729c
– split S 65, S 162
– – diabetes – Type 2 – relatives A 57
Prorenin – serum – albumin excretion rate and – Type 1 diabetes A 34
Protease – renal – streptozotocin-diabetic rat 567
Protein – anabolism – post-prandial – hyperinsulinaemia, role of A 131
– catabolism – exercise, following – Type 1 diabetes 358
– kinase – islet B-cell S 21
– kinase A – insulin secretion, in S 30
– – islet B-cell S 21
– kinase C – fibroblast – insulin, effect of – signal transduction A 122
– – glomerular mesangial cell – glucose, effect of 838
– – insulin receptor – phosphorylation site A 122
– – insulin secretion, in S 30
– – islet – inhibitors – synthetic – myristoylation A 33
– – – peptide YY, lack of effect of 871
– – islet B-cell S 21
– – – intracellular localisation A 102
– – isoenzymes 838
– kinase, Ca^{2+}/calmodulin-dependent – II S 21
– – insulin secretion, in S 30
– – insulin-secreting cell A 33
– kinase, mitogen-activated – islet – rat A 98
– phosphatase – insulin-secreting cell A 102
– – islet A 33
Proteinuria – diabetes – glomerular selectivity 195
Psammomys obesus (sand rat) – diabetes – model for human Type 2 diabetes 671
Psychology *[see also* Diabetes – care; Education; Peer review*]*
– diabetes A 175
– profile – diabetic foot and A 204
Pupillary light reflex – analysis 414
Pyruvate dehydrogenase S 155

Q

Quality of life – Lys(B28),Pro(B29) insulin A 168

R

Radioisotope – gastric emptying, assessment of 543r
Randle, P J – Minkowski Award 1966 S 155
Rat – anococcygeus muscle – nitrergic transmission 233
– BB – diabetes – genetics A 6
– – – Kilham rat virus, induction by – GLUT-2 not involved 1186
– – insulitis – macrophage activity in 466
– – islet B-cell regeneration – cytokine damage, following A 43
– – islet-cell antigen – 38kDa – expression delayed 460
– – lymphocyte – islet B-cell reactive A 97
– – nerve ischaemia 43
– – non-diabetic – islet-cell antibodies A 77
– chylomicron preparation 238
– fetus – insulin secretion 134
– GK Wistar (Goto-Kakizaki Wistar) – diabetes – genetics A 85
– – glucose homeostasis A 112
– – glycogen synthase activation in 885
– – islet B-cell – glucose metabolism 1082
– – – function A 42
– – islet blood flow 677
– – prediabetic – insulin secretion 863
– glomerular – mesangial cell – protein kinase C 838
– hereditary hypercholesterolaemic – calcium channel blocking agent A 147
– hereditary hypertriglyceridaemic A 145
– neonatal – streptozotocin-treated – islet B-cell regeneration 1088
– sand *[see Psammomys obesus]*
– spontaneously hypertensive – retinopathy 32
– Sprague-Dawley – ageing – insulin resistance 969
– streptozotocin-diabetic – aminoguanidine, effect of 10
– – chylomicron clearance 238
– – glucagon, role of 985
– – IGF-I tissue distribution 1073
– – intestinal insulin absorption 119
– – neonatal – cAMP A 115
– – – catecholamine in A 150

– – – insulin secretion 351
– – – islet B-cell regeneration 1088
– – – islet blood flow 677
– – nerve – blood flow – endothelin 1, role of 1209
– – – ischaemia 43
– – – essential fatty acids, effect of 331c
– – neuropathy 651
– – – oxidative stress in 449
– – renal hypertrophy 567
– – vanadium compound, effect of 572, 1065
– urea infusion – renal hyperfiltration 225
– Wistar – NAME, effect of – insulin secretion 879
– Zucker *fa/fa* – glucose transport – thioctic acid isomers, effect of A59
– – GLUT translocation 3
– – homozygosity detection – magnetic resonance proton spectrometry A151
– – insulin resistance S169
– – skeletal muscle – GLUT-1 443
Reaven's syndrome *[see* Insulin – resistance – syndrome*]*
Reaven, Gerald – Claud Bernard Lecturer 1994 *EASD News Section 10/94 41*
Receptor – tyrosine kinase S125
Regeneration – pancreas – gene 994
Regulatory protein – glucokinase S43
Renal – function A187–A192
– – C-peptide and S99
– – dopamine infusion, effect of – diabetes A3
– growth – pregnancy – Type 1 diabetes A173
– histology – diabetes – Type 1 A3
– hypertrophy – diabetes – proteases in 567
– size – diabetes – Type 1 A191
– tubular – cell – growth – proinsulin, effect of A120
– – function – diabetes – retinol-binding protein excretion A194
– – – Tamm-Horsfall protein excretion A189
Renin *[see* Prorenin*]*
Retina *[see also* Visual*]*
– blood-retinal barrier – C-peptide and S99
– endothelial cell – growth factor, effect of A36
– function – diabetes – Type 1 911
– inner – diabetes, abnormalities in 911
– pericyte – Ca^{2+} responses – glucose, effect of A208
– – endothelin, effect of – glucose and 36
– – glycation A68
– taurine uptake – streptozotocin-diabetic rat A207
Retinopathy, diabetic A36, A206–A209
– blindness – incidence A155
– erythrocyte aldose reductase and 328
– glycaemic control – EURODIAB study 278
– preclinical abnormalities 911
– progression – factors predicting A37
– rat model 32
– smoking, effect of A194
RFLP (restriction fragment length polymorphism) – perlecan A4
Risk – calculation – control group selection 845c
– diabetes – Type 1 – infant feeding 381
– – – islet-cell antibodies 491
– – – recurrence in families 321
– – Type 2 – childhood factors 617
– diabetic foot A204
ROC plot *[see* Diagnostic accuracy – receiver-operating characteristic plot*]*

S

S15261 969
Salt sensitivity 308
Schwann cell *[see* Nerve*]*
Screening – diabetic autonomic neuropathy 1168c
Second messenger – insulin secretion, in S30
Selenium – insulin-like effect – streptozotocin-diabetic rat A132
Sequence-specific oligonucleotide – HLA Class II typing – Type 1 diabetes 808
Sex – cardiovascular risk factor, as – fat distribution, role of 757
– hypoglycaemic counterregulation, effect on 797
Sham feeding – IV glucose tolerance, effect on A160
Signalling – insulin receptor S135, S149
– tyrosine kinase receptors S125
Single-photon emission tomography (SPECT) – cerebral blood flow 257
– heart A8
Sjoholm, Åke – Eli Lilly/EASD Res. Fellowship 1994 *EASD News Section 10/94 46*
Skin – lactate release – human A128
– oxygenation – capillary steal and A203
Smoking – microangiopathy, progression of – diabetes A194
Sodium – load – responses – Type 1 diabetes A188
– transport – microalbuminuria and A190
– – Na^+/H^+ – diabetes – Type 2 A15
– – – endothelial cell – glucose, effect of A192
– – Na^+/K^+ ATPase – brain – streptozotocin-diabetic rat A182
– – – obesity, in A133
– – – ouabain binding – diabetic neuropathy A79
– – Na^+/Li^+ counterport – albumin excretion rate and A34
– – – blood pressure and – IDDM A34
– – – diabetes – Type 1 394
– – – fibroblast A192
– – – sex – Type 1 diabetes A142
Somatomedin – C *[see* IGF – I*]*
Somatostatin – analogue – octreotide *[see* Octreotide*]*
– – SMS 201–995 – insulin sensitivity, effect on A130
– nerve conduction, effect on? 1216
Sorbitol – dehydrogenase – inhibitor – CP-166,572 – diab. vascular function A23
SPECT *[see* Single-photon emission tomography*]*
SSO *[see* Sequence-specific oligonucleotide*]*
Starvation S155
Statin *[see* HMG-CoA reductase inhibitor*]*
Statistics – non-parametric – receiver-operating characteristic plot 344
Stephania hernandifolia – serum glucose, effect on – rat A213
Sterol – plant – sitosterol 773
Stomach *[see* Gastric*]*
Streptozotocin – islet B-cell toxicity A82
– nitric oxide generation A102
Stress – mental – insulin sensitivity, effect on 247
Stroke *[see also* Macrovascular disease*]* – diabetes A202
Stroop test – insulin sensitivity, effect on 247
Study Group – Prediction & Prevention Type 1 DM (EGPD1) *EASD News Sect'n 8/94 37w*
Succinic acid esters – insulin secretion, stimulation of A12, A108, S36
– – diabetic rat A113
Sulphatide – tissue distribution 1000
Sulphonylurea – assay A163
– glimepiride A49, A162, A163
– islet B-cell, effect on – Ca^{2+} oscillation 1121
– lipid metabolism, effect on – glipizide 781
– long-term effects – insulin secretion, glucose-stimulated A48
– platelet, effect on 632
– platelet plasminogen activator 1, effect on A24
– protein kinase C and A48
– receptor S21, A48
– – endogenous ligand A61
– – localisation A110
– – photoaffinity labelling A61
– skeletal muscle, effects on A48
– therapy – insulin, combination with A163
Superoxide dismutase *[see* Oxygen – free radicals – scavengers*]*
Syndrome – X – metabolic *[see* Insulin – resistance – syndrome*]*

T

T-cell *[see* Lymphocyte*]*
Täljedal I-B – Minkowski Award 1980 S112
Taurine – retinal uptake – streptozotocin-diabetic rat A207
Temperature – body *[see* Thermoregulation*]*
– skin – insulin absorption, sc, effect on 377
Teratogenesis *[see* Embryo*]*
Thermoregulation – hypoglycaemia, effect of 689
Tooke, John – Camillo Golgi Lecturer 1994 *EASD News Section 10/94 44*
Transphosphatidylation – sugar alcohols – cell membrane incorporation 1147
Transplantation – cyclosporin use – glucose metabolism and A212
– islet A38, A214-A217, *EASD News Section: 6/94 23w, 8/94 33w*
– – function S112
– – human fetal – growth hormone, use of A37
– – isolation, variation of 111
– – NOD mouse 833
– pancreas A214-A215; *EASD News Section: 6/94 23w, 8/94 33w*

– – cardiovascular risk factors following A 37
– – live donor – hemipancreatectomy 1036
Triglyceride *[see also* Hypertriglyceridaemia*]*
– serum – postprandial – diabetes – Type 2 1259
Trophoblast – maternal diabetes, effect of – rat 855
Tumour necrosis factor – α – islet B-cell expression – transgenic mouse 1277
– β – polymorphism – diabetes – Type 2 A 86
– gene – diabetes – Type 1 500
– insulin-secreting cell, effect on 733
– islet toxicity – neonatally streptozotocin-diab.rat A 44

U

Ulcer *[see* Foot – diabetic*]*

V

Van Obberghen, E – Minkowski Award 1985 S 125
Van Schaftigen, E – Minkowski Award 1992 S 43
Vanadium compound – lipogenic enzymes expression, effect on 1065, A 81
– vascular effects – streptozotocin-diabetic rat 572
Vascular – disease *[see also* Macrovascular disease*]* A 54
– – aorta – diabetes – human 286
– – peripheral – ankle/brachial index 223 c
– – – genetics – diabetes A 203
– reactivity – diabetes A 196–A 199
– – – ACE inhibitor, effect of – rat aorta 664
– – – α-adrenergic hypersensitivity – mechanism 664
– – – BRLP-42, effect of A 7
– – – Type 1 – microalbuminuria and 1056
– – – Type 2 A 22
– – diabetic neuropathy, in A 178
– – diazoxide vasodilation – glibenclamide, effect of A 163
– – foot – microangiopathy and A 205
– – hyperglycaemia, effect of 750, A 7
– – hypoxic vasodilatation – diabetes – L-arginine, role of A 23
– – vanadyl, effect of – streptozotocin-diabetic rat 572
– relaxation – endothelium-dependent – BB rat A 152
Vasoactive intestinal polypeptide *[see* VIP*]*
VIP – insulin secretion, effect on – HIT cells A 22
Virus – cytomegalovirus – Type 1 diabetes 222 c
– Kilham rat – diabetes induction in BB rat – GLUT-2 not involved 1186
Visual – evoked potential – photostress recovery – diabetes A 206
– function – predicting diabetic neuropathy? A 207
Vitamin C *[see* Ascorbic acid*]*
Vitamin D – derivative – 1,25 dihydroxycholecalciferol *[see* Calcitriol*]*
Vomiting *[see also* Gastric*]* – diabetes 543 r

W

Wahren, J – Minkowski Award 1977 S 99

X

Xylose meal – gastric emptying, evaluation of A 184